Full Logo No Tagline Color
Donations
Donations
Publications

Publications

We actively contribute our research findings to the professional world.

Publications

We publish latest scientific findings in renowned journals and present them at national and international conferences. In this way, we help shape clinical cancer research and promote scientific dialog at the highest level.

Publication rate of over 95

The Swiss Cancer Institute has a very high publication rate of over 95%. An article published in 2023 examined how often our studies were published, including 240 studies that completed patient recruitment between 1986 and 2021.

216 of 240 studies (90%) were published in peer-reviewed journals, 14 were published in other formats, giving an overall publication rate of 96%.

Studies that were completed earlier were less likely to be published. However, even for these studies, the publication rate was around 80%, which is significantly higher than stated in the literature.

Learn more

Hayoz S, Kasenda B, Schenker AL, et al. Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK). BMJ Open 2023;0:e068490. doi:10.1136/

Publication rate

Facts & Figures

In 2024, 38 articles relating to the Swiss Cancer Institute (formerly SAKK) appeared in various scientific journals. The number of articles is comparable to previous years. Under its former name "SAKK", the Swiss Cancer Institute was well represented with 18 posters and 23 presentations at the most important oncology congresses and local events.

A particular highlight was the oral presentation of the SAKK 41/13 aspirin study at the European Society for Medical Oncology (ESMO) congress in Barcelona. This randomized, placebo-controlled phase III trial investigated the use of adjuvant aspirin treatment in patients with PIK3CA-mutated colorectal cancer.


An overview table with the number of manuscripts and conference presentations compared to previous years can be found in the Annual Report.

Publication Guideline

Publication Guideline [642 KB pdf]
Our services

List of publications

All manuscripts with Swiss Cancer Institute involvement since 2015 can be found in the following list:

Filter Publications

Type
Journal
Year
Trial
Disease Group
Impact Factor

Filter Impact Factor

0
203
Publications
Type
Journal
Year
Disease Group
Trial
Title
Authors
Impact Factor
Type
Swiss Cancer Institute trials
Journal
RADIOTHER ONCOL
Year
2025
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Long-term urinary continence and influencing factors after salvage radiotherapy: Results of the SAKK 0910 dose escalation trial
Authors
Schröder C, Zwahlen DR, Schär S, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Beck M, Riesterer O, Thalmann GN, Aebersold DM, Ghadjar P
Impact Factor
4.9
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2025
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials
Authors
Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG
Impact Factor
56.7
Type
Swiss Cancer Institute trials
Journal
EXP HEMATOL ONCOL
Year
2025
Disease Group
Developmental Therapeutics
Trial
SAKK 11/16
Title
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after = 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
Authors
Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N
Impact Factor
13.5
Type
Swiss Cancer Institute trials
Journal
JTO CLIN RES REP
Year
2025
Disease Group
Lung Cancers
Trial
SAKK 16/XX not operated
Title
Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.
Authors
Raimann S, Schär S, Hayoz S, Guckenberger M, Finazzi T, Opitz I, Schmid S, Mark M, Addeo A, Mauti LA, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D
Impact Factor
3.0
Type
Swiss Cancer Institute trials
Journal
CLIN BREAST CANCER
Year
2025
Disease Group
Breast Cancers
Trial
SAKK 21/12
Title
Final overall survival analysis of the phase II SAKK 21/12 trial of transdermal CR1447 in patients with metastatic breast cancer
Authors
Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B
Impact Factor
2.7
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2025
Disease Group
Breast Cancers
Trial
SAKK 23/16
Title
Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Authors
Knauer M, Egle D, Hayoz S, Sávolt Á, Tausch C, Bucher S, Simonson C, Satler R, Heil J, Bekes I, Bjelic-Radisic V, Audeh W, Lam GT, Menicucci A, Muenst S, Ostapenko V, Kurzeder C, Heidinger M, Weber WP
Impact Factor
7.5
Type
Swiss Cancer Institute trials
Journal
BLOOD
Year
2025
Disease Group
Leukemias
Trial
SAKK 34/17
Title
Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17
Authors
Condoluci A, Romano I, Dietrich D, Pini K, Stüssi G, Müller G, Cantoni N, Cathomas R, Mey U, Widmer A, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi D
Impact Factor
21.0
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2025
Disease Group
Lymphomas
Trial
SAKK 35/10
Title
Rituximab-Lenalidomide as frontline therapy in Follicular Lymphoma Patients: a 10-year Update of the SAKK 35/10 Randomized Trial
Authors
Kimby EK Professor Emerita, Schär S, Pirosa MC, Vanazzi A, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJMJ, Krasniqi F, Voegeli M, Novak U, Zander T, Bersvendsen H, Mamot C, Mingrone W, Stathis A, Dirnhofer S, Hayoz S, Østenstad B, Zucca E
Impact Factor
7.4
Type
Swiss Cancer Institute trials
Journal
CLIN CANCER RES
Year
2025
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/13
Title
Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial
Authors
Güller U, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger M
Impact Factor
10.4
Type
Swiss Cancer Institute services
Journal
SWISS MED WKLY
Year
2025
Disease Group
-
Trial
-
Title
Blastic plasmacytoid dendritic cell neoplasm: A Swiss case series of a very rare disease and a structured review of the literature
Authors
Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg JR, Spertini O, Cantoni N, Betticher D, Simeon L, Medinger M, Hayoz S, Schmidt A
Impact Factor
4.2
Type
Other
Journal
J IMMUNOTHER CANCER
Year
2025
Disease Group
-
Trial
-
Title
Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials
Authors
Özdemir BC, Bill R, Okyar A, Scheiermann C, Hayoz S, Olivier T
Impact Factor
10.3
Type
Meta-analysis
Journal
BRIT J SURG
Year
2025
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable esophageal cancer
Authors
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y
Impact Factor
8.8
Type
Meta-analysis
Journal
ANN SURG
Year
2025
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials
Authors
Okui J, Matsuda S, Nagashima K, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y
Impact Factor
6.4
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2025
Disease Group
Lung Cancers
Trial
ETOP BEAT-meso
Title
A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial
Authors
Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, Stahel R
Impact Factor
56.7
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2025
Disease Group
Lymphomas
Trial
HD 21
Title
Positron Emission Tomography–Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, ingle-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial
Authors
Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Keil F, Ko YD, Hitz F, Schwarz M, Trenker C, Kerkhoff A, Staib P, Wille K, Dresel I, Hahn D, Hertenstein B, Moosmann P, Mey U, Balabanov S, Armytage T, Roncolato F, Hellmuth JC, Hertzberg M, Kobe C, Klapper W, Baues C, Eich HT, Kreissl S, Fuchs M, Jablonski J, Schneider G, Tharmaseelan H, Eichenauer DA, von Tresckow B, Borchmann P, Bröckelmann PJ
Impact Factor
42.1
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2025
Disease Group
Leukemias
Trial
HOVON 132
Title
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Authors
Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevicius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos J
Impact Factor
8.2
Type
Collaborative group trials
Journal
BLOOD ADV
Year
2025
Disease Group
Leukemias
Trial
HOVON 42, HOVON 42A, HOVON 43, HOVON 81, HOVON 92, HOVON 102, HOVON 103, HOVON 132
Title
An Improved Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse
Authors
van der Maas NG, Breems D, Klerk CPW, Pabst T, Gradowska P, Thomas A, Biemond BJ, Kuball J, Van Elssen CHMJ, Visser O, Vekemans MC, Graux C, Maertens J, Knapper S, Dennis M, Freeman S, Thomas I, Beverloo HB, Huls G, Craddock C, Valk PJM, Vyas P, Russell N, Ossenkoppele G, Löwenberg B, Cornelissen JJ, Versluis J
Impact Factor
7.4
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2025
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
Authors
Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW
Impact Factor
35.9
Type
Swiss Cancer Institute trials
Journal
BJU INT
Year
2024
Disease Group
Urogenital Cancers
Trial
SAKK 06/17
Title
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
Authors
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R
Impact Factor
3.7
Type
Swiss Cancer Institute trials
Journal
CLIN TRANSL RADIAT ONCOL
Year
2024
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial
Authors
Zwahlen DR, Schröder C, Holer L, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Martin Putora P, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Giovanni Bosetti D, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebersold DM, Ghadjar P
Impact Factor
3.1
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2024
Disease Group
Lung Cancers
Trial
SAKK 19/17
Title
First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Authors
Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi R, Fischer Maranta A, Bastian S, von Moos R, Joerger M, Früh M
Impact Factor
7.6
Type
Swiss Cancer Institute trials
Journal
SURG ONCOL
Year
2024
Disease Group
Gastrointestinal Cancers
Trial
SAKK 40/00
Title
Is surgical quality more important than radicality? Long-term outcomes of stage I–III colon cancer (SAKK 40/00)
Authors
Maurer CA, Dietrich D, Schilling MK, Brauchli P, Kessler K, Käser SA
Impact Factor
2.3
Type
Swiss Cancer Institute trials
Journal
CLIN COLORECTAL CANC
Year
2024
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/16
Title
Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: a multicenter phase Ib trial (RECAP)–SAKK 41/16
Authors
Bastian S, Joerger M, Holer L, Bärtschi D, Guckenberger M, Jochum W, Koeberle D, Siebenhüner AR, Wicki A, Berger MD, Winterhalder RC, Largiadèr CR, Löffler M, Mosna-Firlejczyk K, Maranta AF, Pestalozzi BC, Csajka C, von Moos R
Impact Factor
3.3
Type
Swiss Cancer Institute trials
Journal
CANCER CHEMO PHARMACOL
Year
2024
Disease Group
Developmental Therapeutics
Trial
SAKK 65/16
Title
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I dose escalation trial (SAKK 65/16)
Authors
Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Sessa C, Stathis A, Halbherr S, Huisinga W, Joerger M, Kloft C
Impact Factor
2.7
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2024
Disease Group
Developmental Therapeutics
Trial
SAKK 65/16
Title
TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)
Authors
Colombo I, Koster K, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Joerger M
Impact Factor
8.4
Type
Swiss Cancer Institute trials
Journal
BONE REP
Year
2024
Disease Group
Developmental Therapeutics
Trial
SAKK 80/19_AlpineTIR
Title
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA study
Authors
Mark M, Mora AR, Winder T, Stathis A, Jakob A, Müller G, Hayoz S, Reimann P, Petrausch U, von Moos R
Impact Factor
4.3
Type
Swiss Cancer Institute services
Journal
CLIN TRANSL RADIAT ONCOL
Year
2024
Disease Group
Radio-Oncology
Trial
-
Title
Deep inspirational breast hold (DIBH) for right breast irradiation: Improved sparing of liver and lung tissue
Authors
Mader T, Pace R, Boucas da Silva RT, Erwin Johannes Adam L, Näf G, Charles Winter C, Maria Aspradakis M, Radovic M, Spyridonidis A, Hayoz S, Gertrud Baumert B
Impact Factor
2.7
Type
Swiss Cancer Institute services
Journal
JIT
Year
2024
Disease Group
Melanomas
Trial
-
Title
Effects of CTLA-4 Single Nucleotide Polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma
Authors
de Joode K, Rojas Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard CL, Läubli H, Michielin H, von Moos R, Joerger M, Levesque MP, Aeppli S, Mangana J, Mangas C, Meyer S, Leoni-Parvex S, Mathijssen R, Metaxas Y
Impact Factor
3.9
Type
Swiss Cancer Institute services
Journal
CAN UROL ASSOC J
Year
2024
Disease Group
Urogenital Cancers
Trial
-
Title
Efficacy and tolerability of Bacillus Calmette-Guérin Strain Russia for the treatment of non-muscle-invasive bladder cancer – analysis of a prospective registry
Authors
Flury-Sutter S, Heuzeroth F, Arbelaez E, Bubendorf L, Püschel H, Hayoz S, Rentsch CA
Impact Factor
1.9
Type
Swiss Cancer Institute services
Journal
J THORAC ONCOL CLIN RES REP
Year
2024
Disease Group
Lung Cancers
Trial
-
Title
First-line chemo-immunotherapy in SCLC: outcomes of a binational real-world study
Authors
Moliner L, Zellweger N, Schmid S, Bertschinger M, Waibel C, Cerciello F, Froesch P, Mark M, Bettini A, Häuptle P, Blum V, Holer L, Hayoz S, Früh M
Impact Factor
3.0
Type
Swiss Cancer Institute services
Journal
J CANCER RES CLIN ONCOL
Year
2024
Disease Group
Urogenital Cancers
Trial
-
Title
Metronomic Cyclophosphamide for Bone Marrow Carcinomatosis in Metastatic Castration-resistant Prostate Cancer
Authors
Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C
Impact Factor
2.7
Type
Swiss Cancer Institute services
Journal
EUR UROL FOCUS
Year
2024
Disease Group
Urogenital Cancers
Trial
-
Title
Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING)
Authors
Wetterauer C, Matthias M, Pueschel H, Deckart A, Bubendorf L, Mortezavi A, Arbelaez E, Jean Winkel D, Heye T, Boll DT, Merkle E, Hayoz S, Seifert HH, Rentsch CA
Impact Factor
4.9
Type
Swiss Cancer Institute services
Journal
SUPPORT CARE CANCER
Year
2024
Disease Group
-
Trial
-
Title
Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single centre study with intrapatient comparison
Authors
Johnson K, Stoffel B, Schwitter M, Hayoz S, Rojas Mora A, Fischer A, El Saadany T, Hasler U, von Moos R, Patzen A, Mark M, Roberts G, Cathomas R
Impact Factor
2.8
Type
Swiss Cancer Institute services
Journal
JTO CLIN RES REP
Year
2024
Disease Group
Lung Cancers
Trial
-
Title
Real-world outcomes of patients with malignant pleural mesothelioma receiving combination ipilimumab and nivolumab as first- or later line treatment
Authors
Schmid S, Holer L, Gysel K, Koster K, Rothschild S, Boos L, Frehner L, Cardoso S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur W, Allemann A, Waibel C, Von der Mühll-Schill C, Frueh M, Maut LA
Impact Factor
3.0
Type
Other
Journal
SWISS MED WKLY
Year
2024
Disease Group
Imaging in Diagnostic and Therapy Monitoring (IDaTM)
Trial
-
Title
Advancements in lung cancer: a comprehensive perspective on diagnosis, staging, therapy and follow-up from the SAKK Working Group on Imaging in Diagnosis and Therapy Monitoring
Authors
Jungblut L, Rizzo SM, Ebner L, Kobe A, Nguyen-Kim TDL, Martini K, Roos J, Puligheddu C, Afshar-Oromieh A, Christe A, Dorn P, Funke-Chambour M, Hötker A, Frauenfelder T
Impact Factor
4.2
Type
Other
Journal
PLOS ONE
Year
2024
Disease Group
Network for Outcomes Research
Trial
-
Title
Cost-Effectiveness & Budget Impact Analysis of Olaparib for BRCA 1/2 Germline-mutated Pancreatic Cancer
Authors
Mehra T, Lupatsch JE, Kössler T, Dedes K, Siebenhüner AR, von Moos R, Wicki A, Schwenkglenks ME
Impact Factor
2.9
Type
Other
Journal
CANCER TREAT REV
Year
2024
Disease Group
-
Trial
-
Title
The active involvement of patients in oncology research
Authors
Ganz-Blaettler U, Liptrott SJ, Tolotti A, Cefalì M, Aeschlimann C, Vilei SB, Colombo I, Hatziandreou E, Kosmidis T, Linardou H, Pfau R, Sgourou S, Sessa C
Impact Factor
9.6
Type
Meta-analysis
Journal
EUR UROL FOCUS
Year
2024
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Better Oncological Outcomes After Prostate-specific Membrane Antigen Positron Emission Tomography–guided Salvage Radiotherapy Following Prostatectomy
Authors
Zamboglou C, Staus P, Wolkewitz M, Peeken JC, Ferentinos K, Strouthos I, Farolfi A, Koerber SA, Vrachimis A, Spohn SKB, Aebersold DM, Grosu AL, Kroeze SGC, Fanti S, Hruby G, Wiegel T, Emmett L, Hayoz S, Ceci F, Guckenberger M, Belka C, Schmidt-Hegemann NS, Ghadjar P, Shelan M
Impact Factor
9.6
Type
Meta-analysis
Journal
J NUCL MED
Year
2024
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma
Authors
Ferrández MC, Golla SSV, Eertink JJ, Wiegers SE, Zwezerijnen GJC, Heymans MW, Lugtenburg PJ, Kurch L, Hüttmann A, Hanoun C, Dührsen U, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Zijlstra JM, Boellaard R; PETRA Consortium
Impact Factor
9.1
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2024
Disease Group
Leukemias
Trial
CLL13
Title
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Authors
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B
Impact Factor
41.6
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2024
Disease Group
Leukemias
Trial
EBMT HCT vs CT
Title
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study
Authors
Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, Cornelissen J
Impact Factor
8.2
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2024
Disease Group
Gynecological Cancers
Trial
ENGOT-en7_AtTEnd
Title
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP
Impact Factor
41.6
Type
Collaborative group trials
Journal
CLIN CANCER RES
Year
2024
Disease Group
Lung Cancers
Trial
ETOP BOOSTER
Title
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Authors
Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA
Impact Factor
10.4
Type
Collaborative group trials
Journal
BLOOD
Year
2024
Disease Group
Leukemias
Trial
GRAALL 2003, GRAALL 2005
Title
NGS-based stratification refines the risk stratification in T-ALL and identifies a Very High-Risk subgroup of patients
Authors
Simonin M, Vasseur L, Lengliné E, Lhermitte L, Cabannes-Hamy A, Balsat M, Schmidt A, Dourthe ME, Touzart A, Graux C, Grardel N, Cayuela JM, Arnoux I, Gandemer V, Rigal-Huguet F, Ducassou S, Lheritier V, Chalandon Y, Ifrah N, Dombret H, Macintyre EA, Petit A, Rousselot P, Lambert J, Baruchel A, Boissel N, Asnafi V
Impact Factor
20.3
Type
Collaborative group trials
Journal
LANCET
Year
2024
Disease Group
Lymphomas
Trial
HD 21
Title
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
Authors
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V
Impact Factor
98.4
Type
Collaborative group trials
Journal
LANCET
Year
2024
Disease Group
Lymphomas
Trial
HD 21
Title
Enhancing the treatment landscape: PET-guided BrECADD for advanced-stage, classical Hodgkin lymphoma
Authors
Evens AM
Impact Factor
98.4
Type
Collaborative group trials
Journal
CELL DEATH DIS
Year
2024
Disease Group
Leukemias
Trial
HOVON 102
Title
High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML)
Authors
Bajrami Saipi M, Ruiba A, Schittenhelm MM, Blumenstock G, Gyorffy B, Fazio S, Hafner M, Ahrens AL, Aldinger L, Aellig V, Kavelaars FG, Nombela-Arrieta C, Fend F, Valk PJM, Christoph D, Kampa-Schittenhelm KM
Impact Factor
8.1
Type
Collaborative group trials
Journal
CANCER REP
Year
2024
Disease Group
Lymphomas
Trial
HOVON 127/ SAKK 37/16
Title
Effectiveness of fractionated rituximab in preventing tumorlysis syndrome in aggressive B-cell lymphoma: Insights fromreal-life clinical practice
Authors
Mohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, Stenner F, Tamburini J, Lang N
Impact Factor
1.5
Type
Collaborative group trials
Journal
BLOOD CANCER J
Year
2024
Disease Group
Leukemias
Trial
HOVON 132
Title
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Authors
van der Maas NG, Versluis J, Nasserinejad K, van Rosmalen J, Pabst T, Maertens J, Breems D, Manz M, Cloos J, Ossenkoppele GJ, Floisand Y, Gradowska P, Löwenberg B, Huls G, Postmus D, Pignatti F, Cornelissen JJ
Impact Factor
12.9
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2024
Disease Group
Leukemias
Trial
HOVON 81, HOVON 103, HOVON 102, HOVON 132
Title
Risk Stratification in Older Intensively Treated Patients With AML
Authors
Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen NA, Kennedy A, Moore R, Boertjes E, Vonk CM, Kavelaars FG, Rijken M, Gilkes A, Schwab C, Beverloo HB, Manz M, Visser O, Van Elssen CHMJ, de Weerdt O, Tick LW, Biemond BJ, Vekemans MC, Freeman SD, Harrison CJ, Cook JA, Dennis M, Knapper S, Thomas I, Craddock C, Ossenkoppele GJ, Löwenberg B, Russell N, Valk PJM, Vyas P
Impact Factor
42.1
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2024
Disease Group
Breast Cancers
Trial
IBCSG 22-00
Title
Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00
Authors
Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thurlimann B, Láng I, Pruneri G, Gray KP, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G
Impact Factor
7.6
Type
Collaborative group trials
Journal
JAMA ONCOL
Year
2024
Disease Group
Breast Cancers
Trial
IBCSG 24-02
Title
Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT Trial
Authors
O’Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell’Orto P, Láng I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, MüllerB, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM
Impact Factor
22.3
Type
Collaborative group trials
Journal
ESMO OPEN
Year
2024
Disease Group
Breast Cancers
Trial
IBCSG 36-07
Title
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer
Authors
de Azambuja E, Piccart-Gebhart M, Fielding S, Townend J, Hillman DW, Colleoni M, Roylance R, Kelly CM, Lombard J, El-abed S, Choudhury A, Korde L, Vicente M, Chumsri S, Rodeheffer R, Ellard SL, Wolff AC, Holtschmidt J, Lang I, Untch M, Boyle F, Xu B, Werutsky G, Tujakowski J, Huang CS, Baruch NB, Bliss J, Ferro A, Gralow J, Kim SB, Kroep JR, Krop I, Kuemmel S, McConnell R, Moscetti L, Knop AS, van Duijnhoven F, Gomez H, Cameron D, Di Cosimo S, Gelber RD, Moreno-Aspitia A
Impact Factor
7.1
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2024
Disease Group
Breast Cancers
Trial
IBCSG 48-14 POSITIVE
Title
Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy
Authors
Azim HA, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Mailliez A , Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe JM, Ruiz-Borrego M, Moore HC, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Tanja Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Peccatori FA
Impact Factor
42.1
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2024
Disease Group
Breast Cancers
Trial
IBCSG 50-14 OLYMPIA
Title
Patient-reported outcomes in OlympiA: A phase III, randomized, placebo-controlled trial of adjuvant olaparib in g BRCA1/2 mutations and high-risk human epidermial growth factor receptor 2-negative early breast cancer
Authors
Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E-M, Armstrong A, Im S-A, Song C-G, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, FrauchigerHeuer H, Wimberger P, t’Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Seok Lee L, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer Jr CE, Tutt ANJ
Impact Factor
42.1
Type
Collaborative group trials
Journal
LANCET
Year
2024
Disease Group
Lymphomas
Trial
TRIANGLE
Title
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
Authors
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E
Impact Factor
98.4
Type
Swiss Cancer Institute trials
Journal
J CLIN ONCOL
Year
2023
Disease Group
Urogenital Cancers
Trial
SAKK 06/17
Title
Perioperative chemo-immunotherapy with Durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single arm phase II trial SAKK 06/17
Authors
Cathomas R, Rothschild SI, Hayoz S, Bubendorf L, Özdemir BC, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel RT, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U
Impact Factor
45.3
Type
Swiss Cancer Institute trials
Journal
BMJ OPEN
Year
2023
Disease Group
Urogenital Cancers
Trial
SAKK 06/19
Title
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single arm phase 2 trial (SAKK 06/19)
Authors
Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R
Impact Factor
3.007
Type
Swiss Cancer Institute trials
Journal
J CLIN ONCOL
Year
2023
Disease Group
Urogenital Cancers
Trial
SAKK 08/16
Title
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
Authors
Gillessen S, Procopio G, Hayoz S, Kremer E, Schwitter M, Caffo O, Lorente D, Pedrazzini A, Roubaud G, Nenan S, Omlin A, Buttigliero C, Delgado Mingorance JI, González-Del-Alba A, Delgado MT, Nole F, Turco F, Pereira Mestre R, Ribi K, Cathomas R
Impact Factor
45.3
Type
Swiss Cancer Institute trials
Journal
ESMO OPEN
Year
2023
Disease Group
Lung Cancers
Trial
SAKK 16/96, SAKK 16/00, SAKK 16/01, SAKK 16/08
Title
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small cell lung cancer. Retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01 and 16/14
Authors
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless M
Impact Factor
7.3
Type
Other
Journal
JAMA ONCOL
Year
2023
Disease Group
Breast Cancers
Trial
SAKK 22/10
Title
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Authors
Huober J, Thürlimann B, Dietrich D
Impact Factor
33.01
Type
Swiss Cancer Institute trials
Journal
JAMA SURG
Year
2023
Disease Group
Breast Cancers
Trial
SAKK 23/16
Title
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer
Authors
Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zimmermann F, Montagna G, Fitzal F, Gnant M, Ruhstaller T, Muenst S, Mueller A, Lelièvre L, Heil J, Knauer M, Egle D, Sávolt Á, Heidinger M, Kurzeder C; TAXIS Study Writing Group; Zwahlen DR, Gruber G, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Smanykó V, Vrieling C, Satler R, Hagen D, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer CF, Loibl S, Winkler J, Lam GT, Fehr MK, Kohlik M, Clerc K, Ostapenko V, Maggi N, Schulz A, Andreozzi M, Goldschmidt M, Saccilotto R, Markellou P.
Impact Factor
16.681
Type
Swiss Cancer Institute trials
Journal
ANN SURG ONCOL
Year
2023
Disease Group
Breast Cancers
Trial
SAKK 23/16
Title
Impact of imaging-guided localization on performance of tailored axillary surgery in patients with clinically node-positive breast cancer: Prospective study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Authors
Weber WP, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz A, Mueller A, Ackerknecht M, Tampaki EC, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanykó V, Hagen D, Müller DJ, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M
Impact Factor
5.344
Type
Swiss Cancer Institute trials
Journal
BREAST CANCER RES TR
Year
2023
Disease Group
Breast Cancers
Trial
SAKK 23/16
Title
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: Prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
Authors
Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz A, Maggi N, Saccilotto R, Heidinger M, Mueller A, Tampaki EC, Bjelic-Radisic V, Sávolt Á, Smanykó V, Hagen D, Müller DJ, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kuemmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer CF, Montagna G, Reitsamer R, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber WP
Impact Factor
4.845
Type
Swiss Cancer Institute trials
Journal
SCI REP
Year
2023
Disease Group
Breast Cancers
Trial
SAKK 24/14
Title
Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative, EGFR positive breast cancer A multicenter single arm phase II trial [SAKK 24/14]
Authors
Mamot C, Wicki A, Hasler-Strub U, Riniker S, Li Q, Holer L, Bärtschi D, Zaman K, von Moos R, Dedes KJ, Boos LA, Novak U, Bodmer A, Ritschard R, Obermann EC, Tzankov A, Ackermann C, Membrez-Antonioli V, Zürrer U, Caspar C, Deuster S, Senn M, Winterhalder R, Rochlitz C
Impact Factor
4.996
Type
Swiss Cancer Institute trials
Journal
eClinicalMedicine
Year
2023
Disease Group
Lymphomas
Trial
SAKK 36/13
Title
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
Authors
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C
Impact Factor
15.1
Type
Swiss Cancer Institute trials
Journal
LEUKEMIA
Year
2023
Disease Group
Lymphomas
Trial
SAKK 39/16
Title
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial
Authors
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C
Impact Factor
12.883
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2023
Disease Group
Sarcomas
Trial
SAKK 57/16
Title
SAKK 57/16 Nab-Paclitaxel And Gemcitabine in soft tissue sarcoma (NAPAGE): Final results from the phase Ib/II trial with >2y median follow up
Authors
Digklia A, Kollár A, Dietrich D, Kronig MN, Britschgi C, Rordorf T, Joerger M, F. Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C
Impact Factor
5.417
Type
Swiss Cancer Institute services
Journal
SWISS MED WKLY
Year
2023
Disease Group
-
Trial
-
Title
A long-term retrospective observational study at a medium-sized medical oncology service in Switzerland: comparison of overall survival with a national cohort and adherence to treatment guidelines
Authors
Gross-Erne M, Zimmerli L, Bassetti S, Li Q, Feller A, Mingrone W
Impact Factor
2.1
Type
Swiss Cancer Institute services
Journal
LUNG CANCER
Year
2023
Disease Group
Lung Cancers
Trial
-
Title
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC): A Swiss cohort study
Authors
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark MT, Rothschild SI, Addeo A, Janthur WD, Siano M, Boos L, Britschgi C, Früh M
Impact Factor
5.3
Type
Swiss Cancer Institute services
Journal
INVEST NEW DRUGS
Year
2023
Disease Group
Developmental Therapeutics
Trial
BASILEA CDI-CS-002
Title
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study
Authors
Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger AF, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A
Impact Factor
3.4
Type
Methodology
Journal
BMJ OPEN
Year
2023
Disease Group
-
Trial
-
Title
Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
Authors
Hayoz S, Kasenda B, Schenker AL, Kopp C, Schär S, Thürlimann B, von Moos R, Pless M
Impact Factor
3.007
Type
Meta-analysis
Journal
EUR J CANCER
Year
2023
Disease Group
Lung Cancers
Trial
SAKK 16/14
Title
Evaluation of radiological response, pathological response and relapse-free survival as the surrogate endpoints for overall survival in the neoadjuvant immunotherapy trials: meta-analyses of individual patient data
Authors
Nie R, Chen F, Provencio M, Wang Y, van den Ende T, van Laarhoven HWM, Yuan S, Pless M, Hayoz S, Zhou Z, Li Y, Rothschild SI, Cai M
Impact Factor
10.002
Type
Meta-analysis
Journal
BLOOD
Year
2023
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
Authors
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM
Impact Factor
10.452
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2023
Disease Group
Leukemias
Trial
CLL13
Title
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
Authors
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber PB, Tadmor T, Lindström V, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Nösslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, van der Klift M, Jäger U, Leys MBL, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink JC, Widmer A, Simon F, De Silva N, Fink AM, Bahlo J, Fischer K, Wendtner CM, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Levin MD, van Oers M, Geisler C, Stilgenbauer S, Hallek M
Impact Factor
59.558
Type
Collaborative group trials
Journal
BLOOD
Year
2023
Disease Group
Leukemias
Trial
CLL13
Title
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
Authors
Fürstenau M, Thus YJ, Robrecht S, Mellink CHM, van der Kevie-Kersemaekers AM, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber PB, Tadmor T, Levin MD, da Cunha-Bang C, Schneider C, Poulsen CB, Illmer T, Schöttker B, Janssens A, Christiansen I, Nösslinger T, Baumann M, Hebart H, Gaska T, Regelink JC, Dompeling EC, Lindström V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink AM, Fischer K, Wendtner CM, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann CU, Hallek M, Eichhorst B, Kreuzer KA, Kater AP
Impact Factor
10.452
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2023
Disease Group
Gastrointestinal Cancers
Trial
DANTE
Title
Perioperative atezolizumab in combination with FLOT chemotherapy vs. FLOT alone for resectable esophagogastric adenocarcinoma: results from the phase II portion of DANTE, a randomized, multicenter, phase II/III trial of the FLOT-AIO German Gastric Cancer Study Group and Swiss Group for Clinical Cancer Research SAKK
Authors
Lorenzen S, Götze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, Lindig U, Heuer V, Kretzschmar A, Goekkurt E, Haag GM, Riera-Knorrenschild J, Bolling C, Hofheinz RD, Zhan T, Angermeier S, Ettrich TJ, Siebenhuener AR, Elshafei M, Bechstein WO, Gaiser T, Loose M, Sookthai D, Kopp C, Pauligk C, Al-Batran SE
Impact Factor
45.3
Type
Collaborative group trials
Journal
CANCERS
Year
2023
Disease Group
Sarcomas
Trial
GISG 11, PazoQoL
Title
Electronic Patient Reported Outcome (ePRO) Measures in Patients with Soft Tissue Sarcoma (STS) Receiving Palliative 3 Treatment
Authors
Hofer, S., Hentschel, L.,Richter, S., Blum, V., Kramer, M., Kasper, B., Riese, C., Schuler, M.K
Impact Factor
6.639
Type
Collaborative group trials
Journal
BLOOD
Year
2023
Disease Group
Leukemias
Trial
GRAALL 2003, GRAALL 2005, GRAALL 2014
Title
Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study
Authors
Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, Passet M, Grardel N, Delabesse E, Kubetzko S, Caye-Eude A, Meyer C, Marschalek R, Lafage-Pochitaloff M, Thiebaut-Bertrand A, Balsat M, Escoffre-Barbe M, Blum S, Baumann M, Banos A, Straetmans N, Gallego-Hernanz MP, Chalandon Y, Graux C, Soulier J, Leguay T, Hunault M, Huguet F, Lhéritier V, Dombret H, Boissel N, Clappier E
Impact Factor
10.452
Type
Collaborative group trials
Journal
BLOOD
Year
2023
Disease Group
Leukemias
Trial
GRAALL 2003, GRAALL 2005
Title
Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL
Authors
Simonin M, Andrieu GP, Birsen R, Balsat M, Hypolite G, Courtois L, Graux C, Grardel N, Cayuela JM, Huguet F, Chalandon Y, Le Bris Y, Macintyre E, Gandemer V, Petit A, Rousselot P, Baruchel A, Bouscary D, Hermine O, Boissel N, Asnafi V
Impact Factor
10.452
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2023
Disease Group
Leukemias
Trial
GRAALL 2005
Title
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study
Authors
Orvain C, Chantepie S, Thomas X, Escofrre-Barbe M, Huguet F, Desbrosses Y, Guillerm G, Uzunov M, Leguay T, Barbieux S, Vey N, Chevallier P, Malfuson JV, Lepretre S, Baumann M, Aykut M, Chaib A, Joris M, Zerazhi H, Stussi G, Chapiro J, Berthon C, Bonmati C, Jourdan E, Carp D, Marcais AR, Gallego-Hernanz MP, Vaida I, Bilger K, Villate A, Pasquier F, Chalandon Y, Maury S, Lheritier V, Ifrah N, Dombret H, Boissel N, Hunault-Berger M
Impact Factor
11.04
Type
Collaborative group trials
Journal
BLOOD CANCER DISCOV
Year
2023
Disease Group
Leukemias
Trial
GRAALL 2014
Title
Adult Low-Hypodiploid Acute Lymphoblastic Leukemia Emerges from Preleukemic TP53-Mutant Clonal Hematopoiesis
Authors
Kim R, Bergugnat H, Larcher L, Duchmann M, Passet M, Gachet S, Cuccuini W, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Schafer BW, Delabesse E, Itzykson R, Ades L, Hicheri Y, Chalandon Y, Graux C, Chevallier P, Hunault M, Leguay T, Huguet F, Lheritier V, Dombret H, Soulier J, Rousselot P, Boissel N, Clappier E
Impact Factor
-
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2023
Disease Group
Lymphomas
Trial
HD 16
Title
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
Authors
Fuchs M, Jacob AS, Kaul H, Kobe C, Kuhnert G, Pabst T, Greil R, Bröckelmann PJ, Topp MS, Just M, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Dührsen U, Meissner J, Viardot A, Eich HT, Baues C, Diehl V, Rosenwald A, Buehnen I, von Tresckow B, Dietlein M, Borchmann P, Engert A, Eichenauer DA
Impact Factor
10.431
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2023
Disease Group
Lymphomas
Trial
HD 18
Title
Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced stage Hodgkin Lymphoma: results from the randomized international GHSG HD18 trial
Authors
Ferdinandus J, Müller H, Damaschin C, Jacob AS, Meissner J, Krasniqi F, Mey U, Schöndube D, Thiemer J, Mathas S, Zijlstra J, Greil R, Feuring-Buske M, Markova J, Rüffer JU, Kobe C, Eich HT, Baues C, Fuchs M, Borchmann P, Behringer K
Impact Factor
50.5
Type
Collaborative group trials
Journal
BLOOD
Year
2023
Disease Group
Lymphomas
Trial
HD 16, HD 17
Title
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studies
Authors
Eichenauer DA, Bühnen I, Baues C, Kobe C, Kaul H, Greil R, Moccia A, Zijlstra JM, Hertenstein B, Topp MS, Just M, von Tresckow B, Eich HT, Fuchs M, Dietlein M, Hartmann S, Engert A, Borchmann P
Impact Factor
10.452
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2023
Disease Group
Lymphomas
Trial
HOVON 127/ SAKK 37/16
Title
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Authors
Chamuleau MED, Stenner F, Chitu DA, Novak U, Minnema MC, Geerts P, Stevens WBC, Zenz T, van Imhoff GW, Wu KL, Demandt AMP, Kersten MJ, Terpstra WE, Tick LW, Deeren D, Van Den Neste E, Gregor M, Veelken H, Böhmer LH, Caspar CB, Mutsaers P, Refos JM, Sewsaran R, Fu L, Seefat RL, Uyl-de Groot CA, Dirnhofer S, Van Den Brand M, de Jong D, Nijland M, Lugtenburg P
Impact Factor
24.7
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2023
Disease Group
Leukemias
Trial
HOVON 132
Title
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
Authors
Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J
Impact Factor
11.047
Type
Collaborative group trials
Journal
BLOOD
Year
2023
Disease Group
Leukemias
Trial
HOVON 132
Title
Prospective validation of CD34+CD38- Leukemic Stem Cell frequency in the HOVON-SAKK132 trial
Authors
Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, Kelder A, Oudshoorn-van Marsbergen L, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevicius L, Juliusson G, van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, Cloos J
Impact Factor
21.0
Type
Collaborative group trials
Journal
BLOOD CANCER J
Year
2023
Disease Group
Leukemias
Trial
HOVON 135
Title
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Authors
Hilberink JR, van Zeventer IA, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research (SAKK); Huls G.
Impact Factor
8.125
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2023
Disease Group
Breast Cancers
Trial
IBCSG 48-14 POSITIVE
Title
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer
Authors
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim Jr HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy KJ, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O
Impact Factor
176.079
Type
Collaborative group trials
Journal
BR J CANCER
Year
2023
Disease Group
Gynecological Cancers
Trial
INOVATYON
Title
INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Authors
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A
Impact Factor
9.075
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2023
Disease Group
Gastrointestinal Cancers
Trial
PROSPECT
Title
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)
Authors
Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O’Reilly E, Meyerhardt JA, Shi Q, Schrag D
Impact Factor
45.3
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2023
Disease Group
Gastrointestinal Cancers
Trial
PROSPECT
Title
Preoperative Treatment of Locally Advanced Rectal Cancer
Authors
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, Goldberg J, Al Baghdadi T, Goodman KA, McWilliams RR, Farma JM, George TJ, Kennecke HF, Shergill A, Montemurro M, Nelson GD, Colgrove B, Gordon V, Venook AP, O’Reilly EM, Meyerhardt JA, Dueck AC, Basch E, Chang GJ, Mamon HJ
Impact Factor
96.2
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2023
Disease Group
Lymphomas
Trial
REMoDL-B
Title
Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to molecular subgroup in the REMoDL-B study with 5 years follow up
Authors
Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWM
Impact Factor
50.717
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2023
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
Authors
Attard G, Murphy L, Clarke NW, Sachdeva A, Jones C, Hoyle A, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Gilson C, Rush H, Abdel-Aty H, Amos CL, Murphy C, Chowdhury S, Malik Z, Russell JM, Parkar N, Pugh C, Diaz-Montana C, Pezaro C, Grant W, Saxby H, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzouebi M, Parikh O, Robinson A, Montazeri AH, Wylie J, Zarkar A, Cathomas R, Brown MD, Jain Y, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; STAMPEDE investigators
Impact Factor
54.433
Type
Swiss Cancer Institute trials
Journal
LANCET ONCOL
Year
2022
Disease Group
Urogenital Cancers
Trial
SAKK 01/10
Title
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA/B seminoma: SAKK 01/10
Authors
Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, Krege S, Lorch A, Aebersold DM, Putora PM, Berthold DR, Zihler D, Zengerling F, Dieing A, Mueller AC, Schaer C, Biaggi C, Gillessen S, Cathomas R
Impact Factor
54.433
Type
Swiss Cancer Institute trials
Journal
EUR UROL ONCOL
Year
2022
Disease Group
Urogenital Cancers
Trial
SAKK 06/14
Title
Results of a phase II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin (rBCG) VPM1002BC in patients with high-grade non muscle-invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14
Authors
Rentsch CA, Thalmann GN, Lucca I, Kwiatkowski M, Wirth GJ, Strebel RT, Engeler D, Pedrazzini A, Hüttenbrink C, Schultze-Seemann W, Torpai R, Bubendorf L, Wicki A, Roth B, Bosshard P, Püschel H, Boll DT, Hefermehl L, Roghmann F, Gierth M, Ribi K, Schäfer S, Hayoz S
Impact Factor
7.479
Type
Swiss Cancer Institute trials
Journal
INT J RADIAT ONCOL BIOL PHYS
Year
2022
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Adherence to contouring and treatment planning requirements within a multicentric trial -results of the quality assurance of the SAKK 09/10 trial
Authors
Beck M, Sassowsky M, Schär S, Mathier E, Halter M, Zwahlen DR, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Hayoz S, Schär C, Li Q, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Aebersold DM, Ghadjar P, Pra AD
Impact Factor
4.495
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2022
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Validation of the Decipher Genomic Classifier in SAKK 09/10: A Phase 3 Randomized Trial of Dose-escalated Salvage Radiotherapy after Radical Prostatectomy
Authors
Dal Pra A, Ghadjar P, Hayoz S, Liu VYT, Spratt DE, Thompson DJS, Davicioni E, Huang HC, Zhao X, Liu Y, Schär C, Gut P, Plasswilm L, Hölscher T, Polat B, Hildebrandt G, Müller AC, Pollack A, Thalmann GN, Zwahlen D, Aebersold DM
Impact Factor
7.04
Type
Swiss Cancer Institute trials
Journal
CELL
Year
2022
Disease Group
Lung Cancers
Trial
SAKK 16/14
Title
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Authors
Lötscher J, Martí I Líndez AA, Kirchhammer N, Cribioli E, Giordano Attianese GMP, Trefny MP, Lenz M, Rothschild SI, Strati P, Künzli M, Lotter C, Schenk SH, Dehio P, Löliger J, Litzler L, Schreiner D, Koch V, Page N, Lee D, Grählert J, Kuzmin D, Burgener AV, Merkler D, Pless M, Balmer ML, Reith W, Huwyler J, Irving M, King CG, Zippelius A, Hess C
Impact Factor
41.582
Type
Swiss Cancer Institute trials
Journal
J THORAC CARDIOVASC SURG
Year
2022
Disease Group
Lung Cancers
Trial
SAKK 16/96, SAKK 16/00, SAKK 16/01
Title
Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatment
Authors
Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, Krueger T, Perentes JY, Schmid RA, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel RA, Rothschild SI, Hayoz S, Opitz I.
Impact Factor
5.209
Type
Swiss Cancer Institute trials
Journal
ESMO OPEN
Year
2022
Disease Group
Lung Cancers
Trial
SAKK 16/96, SAKK 16/00, SAKK 16/01, SAKK 16/08
Title
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era. Results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
Authors
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M
Impact Factor
5.329
Type
Swiss Cancer Institute trials
Journal
JTO CLIN RES REP
Year
2022
Disease Group
Lung Cancers
Trial
SAKK 17/04
Title
Viral mimicry response is associated with clinical outcome in pleural mesothelioma
Authors
Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
ESMO OPEN
Year
2022
Disease Group
Lung Cancers
Trial
SAKK 17/16
Title
Long term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): Follow-up efficacy and translational part of the SAKK 17/16 study
Authors
Mark M, Rusakiewicz S, Früh M, Hayoz S, Grosso F, Pless M, Zucali P, Ceresoli GL, Maconi A, Schneider M, Froesch P, Tarussio D, Benedetti F, Dagher J, Kandalaft L, von Moos R, Tissot-Renaud S, Schmid S, Metaxas Y
Impact Factor
5.329
Type
Swiss Cancer Institute trials
Journal
LUNG CANCER
Year
2022
Disease Group
Lung Cancers
Trial
SAKK 19/18
Title
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: the SAKK 19/18 phase II study
Authors
Addeo A, Rothschild SI, Holer L, Schneider M, Waibel C, Haefliger S, Mark M, Fernandez E, Mach N, Mauti L, Jermann PM, Alborelli I, Calgua B, Savic-Prince S, Joerger M, Früh M
Impact Factor
6.081
Type
Swiss Cancer Institute trials
Journal
ENDOCRINE ONCOLOGY
Year
2022
Disease Group
Breast Cancers
Trial
SAKK 21/12
Title
SAKK 21/12 - A stratified, multicenter Phase II trial of transdermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer
Authors
Vetter M, Rothgiesser KM, Qiyu L, Hawle H, Schönfeld W, Ribi K, Riniker S, von Moos R, Trojan A, Kralidis E, Fehr M, Müller A, Thuerlimann B
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
J GERIATR ONCOL
Year
2022
Disease Group
Breast Cancers
Trial
SAKK 25/14
Title
Eribulin as first-line treatment in elderly patients (=70years) with advanced breast cancer: a multicenter Phase II trial [SAKK 25/14]
Authors
Hasler-Strub U, Mueller A, Li Q, Thuerlimann B, Ribi K, Gerber S, von Moos R, Fehr M, Rochlitz C, Zaman K, Aebi S, Hochstrasser A, Gick U, Baertschi D, Greuter S, Schreiber A, Caspar C, Trojan A, Condorelli R, Ruhstaller T
Impact Factor
3.929
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2022
Disease Group
Lymphomas
Trial
SAKK 35/15
Title
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
Authors
Stathis A, Mey UJM, Schär S, Hitz F, Pott C, Mach N, Krasniqi F, Novak U, Schmidt C, Hohloch K, Kienle DL, Hess D, Moccia AA, Unterhalt M, Eckhardt K, Hayoz S, Forestieri G, Rossi D, Dirnhofer S, Ceriani L, Sartori G, Bertoni F, Buske C, Zucca E, Hiddemann W
Impact Factor
6.799
Type
Swiss Cancer Institute trials
Journal
CANCERS
Year
2022
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Integration of baseline metabolic parameters and mutational profile predict long-term response to first-line therapy in DLBCL patients. A post hoc analysis of SAKK38/07 study (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) parameters, combined with muta
Authors
Genta S, Ghilardi G, Cascione L, Juskevicius D, Tzankov A, Schär S, Milan L, Pirosa MC, Esposito F, Ruberto T, Giovanella L, Hayoz S, Mamot C, Dirnhofer S, Zucca E, Ceriani L
Impact Factor
6.639
Type
Swiss Cancer Institute trials
Journal
BJCP
Year
2022
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/16
Title
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)
Authors
Schmulenson E, Bovet C, Theurillat R, Decosterd LA, Largiadèr CR, Prost JC, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Joerger M, Jaehde U
Impact Factor
3.716
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2022
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial
Authors
Panje C, Hayoz S, Eisterer W, Hess V, Thuss-Patience P, Schacher S, Dürr D, Wagner AD, Girschikofsky M, Eboulet E, Stahl M, Ruhstaller T
Impact Factor
9.162
Type
Swiss Cancer Institute trials
Journal
CANCERS
Year
2022
Disease Group
Developmental Therapeutics
Trial
SAKK 80/20_CaSA
Title
Outcome and prognostic factors of COVID-19 infection in Swiss cancer patients: Final results of SAKK 80/20 (CaSA)
Authors
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos R
Impact Factor
6.162
Type
Swiss Cancer Institute services
Journal
EUR UROL OPEN SCI
Year
2022
Disease Group
Urogenital Cancers
Trial
-
Title
Prediction of Biochemical Recurrence Based on Molecular Detection of Lymph Node Metastasis After Radical Prostatectomy
Authors
Oezdemir BC, Arnold N, Fleischmann A, Hensel J, Klima I, Kruithof-de Julio M, Burkhard F, Hayoz S, Kiss B, Thalmann GM
Impact Factor
3.0
Type
Swiss Cancer Institute services
Journal
BIOLOGY
Year
2022
Disease Group
Melanomas
Trial
-
Title
Prescription patterns, recurrence and toxicity rates of adjuvant treatment for stage III/IV melanoma- A real world single-centre analysis
Authors
Hoffmann M, Hayoz S, Özdemir B C
Impact Factor
5.007
Type
Swiss Cancer Institute services
Journal
J CANCER RES CLIN ONCOL
Year
2022
Disease Group
Breast Cancers
Trial
-
Title
Prognostic relevance of mixed histological subtypes in invasive breast carcinoma: a retrospective analysis
Authors
Rechsteiner A, Dietrich D, Varga Z
Impact Factor
4.322
Type
Swiss Cancer Institute services
Journal
J CANCER RES CLIN ONCOL
Year
2022
Disease Group
-
Trial
-
Title
The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex
Authors
Wahli MN, Hayoz S, Hoch D, Ryser CO, Hoffmann M, Scherz A, Schwacha-Eipper B, Häfliger S, Wampfler J, Berger MD, Novak U, Özdemir BC
Impact Factor
4.322
Type
Collaborative group trials
Journal
LUNG CANCER
Year
2022
Disease Group
Lung Cancers
Trial
ETOP ALERT
Title
Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial
Authors
Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans A-MC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R.
Impact Factor
6.081
Type
Collaborative group trials
Journal
ESMO OPEN
Year
2022
Disease Group
Lung Cancers
Trial
ETOP BOOSTER
Title
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC – A systematic review and meta-analysis
Authors
Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, Han JY, De Castro J, Coate L, Früh M, Hashemi SMS, Nadal E, Carcereny E, Sala MA, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA
Impact Factor
6.54
Type
Collaborative group trials
Journal
LUNG CANCER
Year
2022
Disease Group
Lung Cancers
Trial
ETOP PROMISE-meso
Title
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9 15 PROMISE-meso phase III trial
Authors
Banna G L, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA
Impact Factor
5.705
Type
Collaborative group trials
Journal
LUNG CANCER
Year
2022
Disease Group
Lung Cancers
Trial
ETOP SPLENDOUR
Title
Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial.
Authors
Peters S, Letovanec I, Mauer, M, Dafni U, Ejedepang D, Biernat W, Bubendorf L, Warth,A, Pokharel S, Reinmuth N, Majem Tarruella M, Casas-Martin J, Tsourti Z, Marti N, Kammler R, Danson S, O'Brien M, Stahel RA
Impact Factor
3.958
Type
Collaborative group trials
Journal
BMC CANCER
Year
2022
Disease Group
Lymphomas
Trial
HD 16
Title
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial
Authors
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin CA, Kobe C
Impact Factor
4.638
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2022
Disease Group
Leukemias
Trial
HOVON 103 - SEL
Title
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with AML and high risk MDS
Authors
Janssen JJWM, Löwenberg B, Manz M, Biemond BJ, Westerweel PE, Klein SK, Fehr M, Sinnige HAM, Efthymiou A, Legdeur MCJC, Pabst T, Gregor M, van der Poel MWM, Deeren D, Tick LW, Jongen-Lavrencic M, van Obbergh F, Boersma RS, de Weerdt O, Chalandon Y, Heim D, Spertini O, van Sluis G, Graux C, Stüssi G, van Norden Y, Ossenkoppele GJ
Impact Factor
11.528
Type
Collaborative group trials
Journal
FRONT ONCOL
Year
2022
Disease Group
Leukemias
Trial
HOVON 92, HOVON 102, HOVON 103, HOVON 132
Title
Concordance in Measurable Residual Disease result and outcome after first- and second induction cycle in Acute Myeloid Leukemia
Authors
Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ
Impact Factor
6.244
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2022
Disease Group
Breast Cancers
Trial
IBCSG 24-02
Title
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
Authors
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE Jr, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM, for the SOFT Investigators and the International Breast Cancer Study Group
Impact Factor
50.717
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2022
Disease Group
Breast Cancers
Trial
IBCSG 24-02, IBCSG 25-02
Title
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Authors
Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA
Impact Factor
50.717
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2022
Disease Group
Breast Cancers
Trial
IBCSG 24-02, IBCSG 25-02
Title
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
Authors
Bradley R, Braybrooke J, Gray R, Hills R, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C, Bergh J, Swain S, Francis PA, Gnant M, Perrone F, Regan MM
Impact Factor
41.316
Type
Collaborative group trials
Journal
LANCET
Year
2022
Disease Group
Breast Cancers
Trial
IBCSG 38-10
Title
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study
Authors
Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu T TT, Muanza TM, Neal A, Olivotto IA, BIG 3–07/TROG 07.01 trial investigators
Impact Factor
202.731
Type
Collaborative group trials
Journal
JAMA
Year
2022
Disease Group
Breast Cancers
Trial
IBCSG 40-11
Title
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Authors
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR
Impact Factor
56.272
Type
Collaborative group trials
Journal
INT J CANCER
Year
2022
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)
Authors
James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O'Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, Sydes MR
Impact Factor
7.316
Type
Collaborative group trials
Journal
JNCI CANCER SPECTR
Year
2022
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
Authors
James ND, Ingleby FC, Clarke NW, Amos CL, Attard G, Brawley CD, Chowdhury S, Cross W, Dearnaley DP, Gilbert DC, Gillessen S, Jones RJ, Langley RE, Macnair A, Malik ZI, Mason MD, Matheson DJ, Millman R, Parker CC, Rush HL, Russell JM, Au C, Ritchie AWS, Mestre RP, Ahmed I, Birtle AJ, Brock SJ, Das P, Ford VA, Gray EK, Hughes RJ, Manetta CB, McLaren DB, Nikapota AD, O'Sullivan JM, Perna C, Peedell C, Protheroe AS, Sundar S, Tanguay JS, Tolan SP, Wagstaff J, Wallace JB, Wylie JP, Zarkar A, Parmar MKB, Sydes MR.
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
EUR UROL
Year
2021
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Dose-intensified versus conventional dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 randomised phase 3 trial
Authors
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Schär C, Sumila M, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti DG, Khanfir K, Gomez S, Wust P, Thalmann GN, Aebersold DM
Impact Factor
13.938
Type
Swiss Cancer Institute trials
Journal
BR J RADIOL
Year
2021
Disease Group
Lung Cancers
Trial
SAKK 16/00
Title
Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types
Authors
Denzler S, Vuong D, Bogowicz M, Pavic M, Frauenfelder T, Thierstein S, Eboulet EI, Maurer B, Schniering J, Gabrys HS, Schmitt-Opitz I, Pless M, Foerster R, Guckenberger M, Tanadini-Lang S.
Impact Factor
2.196
Type
Swiss Cancer Institute trials
Journal
EJNMMI RESEARCH
Year
2021
Disease Group
Lung Cancers
Trial
SAKK 16/00
Title
Preselection of robust radiomics features does not improve outcome modelling in non-small cell lung cancer based on clinical routine FDG-PET imaging
Authors
Oliveira C, Amstutz F, Vuong D, Bogowicz M, Hüllner M, Foerster R, Basler L, Schröder C, Eboulet EI, Pless M, Thierstein S, Peters S, Hillinger S, Tanadini-Lang S, Guckenberger M.
Impact Factor
2.73
Type
Swiss Cancer Institute trials
Journal
SCI REP
Year
2021
Disease Group
Lung Cancers
Trial
SAKK 16/00
Title
Quantification of spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC
Authors
Vuong D, Bogowicz M, Wee L, Riesterer O, Vlaskou Badra E, D'Cruz LA, Balermpas P, van Timmeren JE, Burgermeister S, Dekker A, De Ruysscher D, Unkelbach J, Thierstein S, Eboulet EI, Peters S, Pless M, Guckenberger M, Tanadini-Lang S.
Impact Factor
4.379
Type
Swiss Cancer Institute trials
Journal
J CLIN ONCOL
Year
2021
Disease Group
Lung Cancers
Trial
SAKK 16/14
Title
SAKK 16/14: Durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer — A multicentre single-arm phase II trial.
Authors
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M
Impact Factor
18.428
Type
Swiss Cancer Institute trials
Journal
LUNG CANCER
Year
2021
Disease Group
Lung Cancers
Trial
SAKK 19/16
Title
Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
Authors
Froesch P, Mark M, Rothschild SI, Li Q, Godar G, Rusterholz C, Oppliger Leibundgut E, Schmid S, Colombo I, Metaxas Y, König D, Sessa C, Gautschi O, Früh M
Impact Factor
3.958
Type
Swiss Cancer Institute trials
Journal
THE BREAST
Year
2021
Disease Group
Breast Cancers
Trial
SAKK 23/16
Title
Implementation of Tailored Axillary Surgery for Patients with Clinically Node-Positive Breast Cancer: Prospective Study within SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101
Authors
Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Seiler S, Maddox C, Ruhstaller T, Muenst S, Ackerknecht M, Kuemmel S, Bjelic-Radisic V, Kurzeder C, Újhelyi M, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, Dubsky P, Exner R, Fansa H, Hager C, Reisenberger K, Singer CF, Reitsamer R, Reinisch M, Winkler J, Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Nussbaumer R, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M
Impact Factor
4.38
Type
Swiss Cancer Institute trials
Journal
CLIN LYMPHOMA MYELOMA LEUK
Year
2021
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma
Authors
Greuter M, Eertink JJ, Jongeneel G, Dührsen U, Hüttmann A, Schmitz C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Carr R, Györke T, Burggraaff CN, de Vet H, Hoekstra OS, Zijlstra JM, Coupé V; PETRA consortium
Impact Factor
3.231
Type
Swiss Cancer Institute trials
Journal
HEMATOL ONCOL
Year
2021
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis
Authors
Ceriani L, Milan L, Cascione L, Gritti G, Dalmasso F, Esposito F, Pirosa MC, Schär S, Bruno A, Dirnhofer S, Giovanella L, Hayoz S, Mamot C, Rambaldi A, Chauvie S, Zucca E
Impact Factor
3.084
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2021
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients
Authors
Eertink JJ, Burggraaff CN, Heymans MW, Dührsen U, Hüttmann A, Schmitz C, Müller S, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Carr R, Czibor S, Györke T, Ceriani L, Zucca E, Hutchings M, Kostakoglu L, Loft A, Fanti S, Wiegers SE, Pieplenbosch S, Boellaard R, Hoekstra OS, Zijlstra JM, de Vet HCW
Impact Factor
4.91
Type
Swiss Cancer Institute trials
Journal
SWISS MED WKLY
Year
2021
Disease Group
Supportive Care
Trial
SAKK 95/16
Title
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study
Authors
Stoffel ST, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D, Schwenkglenks M, Lupatsch JE, Mark MT
Impact Factor
1.821
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2021
Disease Group
Supportive Care
Trial
SAKK 95/16
Title
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)
Authors
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar C, Moos R, Mark M
Impact Factor
7.04
Type
Other
Journal
EUR J HEALTH ECON
Year
2021
Disease Group
Lung Cancers
Trial
-
Title
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with advanced non-small cell lung cancer and high PD-L1 expression in Switzerland.
Authors
Barbier MC, Pardo E, Panje CM, Gautschi O, Lupatsch JE
Impact Factor
2.367
Type
Other
Journal
LANCET ONCOL
Year
2021
Disease Group
Urogenital Cancers
Trial
-
Title
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer
Authors
Rentsch CA, Hayoz S, Cathomas R.
Impact Factor
41.316
Type
Other
Journal
J NATL CANCER INST
Year
2021
Disease Group
Supportive Care
Trial
SAKK 95/16
Title
RE:Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer
Authors
Mark M, von Moos R, Cathomas R, Stoffel A, Gillessen S
Impact Factor
13.506
Type
Meta-analysis
Journal
LANCET ONCOL
Year
2021
Disease Group
Cancers of Head and Neck
Trial
SAKK 10/94
Title
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis
Authors
Petit C, Lacas B, Pignon JP, Le QT, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar MKB, Lee JW, Ghi MG, Sanguineti G, Temam S, Cheugoua-Zanetsie M, O'Sullivan B, Posner MR, Vokes EE, Cruz Hernandez JJ, Szutkowski Z, Lartigau E, Budach V, Suwinski R, Poulsen M, Kumar S, Ghosh Laskar S, Mazeron JJ, Jeremic B, Simes J, Zhong LP, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P; MACH-NC and MARCH Collaborative Groups.
Impact Factor
41.316
Type
Meta-analysis
Journal
RADIOTHER ONCOL
Year
2021
Disease Group
Cancers of Head and Neck
Trial
SAKK 10/94
Title
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group
Authors
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Grazia Ghi M, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Ghosh Laskar S, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zaktonik B, Sharma A, Bensadoun RJ, Grazia Ruo Redda M, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Takácsi Nagy Z, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P
Impact Factor
4.856
Type
Meta-analysis
Journal
EUR J SURG ONCOL
Year
2021
Disease Group
Gastrointestinal Cancers
Trial
SAKK 40/00
Title
Comparative surgical and oncological outcomes of upper rectal versus rectosigmoid tumours: A systematic review and meta-analysis
Authors
Morarasu S, O’Brien L, Clancy C, Dietrich D, Maurer C, Frasson M, Garcia-Granero E, Martin ST
Impact Factor
4.424
Type
Meta-analysis
Journal
CANCER TREAT REV
Year
2021
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/06
Title
Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies.
Authors
Salvatore L, Bria E, Sperduti I, Hinke A, Hegewisch-Becker S, Aparicio T, Le Malicot K, Boige V, Koeberle D, Baertschi D, Dietrich D10, Tortora G, Arnold D
Impact Factor
3.619
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2021
Disease Group
Lung Cancers
Trial
ETOP BOOSTER
Title
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
Authors
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Pulla MP, Campelo RG, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators
Impact Factor
32.976
Type
Collaborative group trials
Journal
LUNG CANCER
Year
2021
Disease Group
Lung Cancers
Trial
ETOP SPLENDOUR
Title
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
Authors
Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M.
Impact Factor
3.958
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2021
Disease Group
Lymphomas
Trial
HD 14
Title
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)
Authors
Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS, Meissner J, Zijlstra JM, Eichenauer DA, Bröckelmann PJ, Diehl V, Borchmann P, Engert A, von Tresckow B.
Impact Factor
10.406
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2021
Disease Group
Lymphomas
Trial
HD 17
Title
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
Authors
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A.
Impact Factor
41.316
Type
Collaborative group trials
Journal
BR J HAEMATOL
Year
2021
Disease Group
Lymphomas
Trial
HD 18
Title
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
Authors
Kreissl S, Voltin CA, Kaul H, Bühnen I, Mettler J, Pabst T, Eichenauer DA, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Kobe C.
Impact Factor
5.67
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2021
Disease Group
Lymphomas
Trial
HD 18
Title
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Authors
Kreissl S, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P
Impact Factor
18.959
Type
Collaborative group trials
Journal
CANCERS
Year
2021
Disease Group
Leukemias
Trial
HOVON 102
Title
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
Authors
Hanekamp D, Tettero JM, Ossenkoppele GJ, Kelder A, Cloos J, Schuurhuis GJ
Impact Factor
6.639
Type
Collaborative group trials
Journal
CANCER MED
Year
2021
Disease Group
Leukemias
Trial
HOVON 102
Title
The added value of multi-state modelling in a randomized controlled trial: the HOVON 102 study re-analyzed
Authors
Bakunina K, Putter H, Versluis J, Koster EAS, van der Holt B, Manz MG, Breems DA, Gjertsen BT, Cloos J, Valk PJM, Passweg J, Pabst T, Ossenkoppele GJ, Löwenberg B, Cornelissen JJ, de Wreede LC
Impact Factor
3.362
Type
Collaborative group trials
Journal
ANN HEMATOL
Year
2021
Disease Group
Leukemias
Trial
HOVON 103 - LEN
Title
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Authors
Brune MM, Stüssi G, Lundberg P, Vela V, Heim D, Manz MG, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Grobholz R, Fehr M, Cogliatti S, Ossenkoppele GJ, Löwenberg B, Rudolf CB, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A
Impact Factor
2.904
Type
Collaborative group trials
Journal
CANCERS
Year
2021
Disease Group
Leukemias
Trial
HOVON 103 - TOS
Title
Addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with AML and high risk MDS
Authors
Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, Borne PVD, Breems D, Brouwer R, Chalandon Y, Deeren D, Efthymiou A, Gjertsen BT, Graux C, Gregor M, Heim D, Hess U, Hoogendoorn M, Jaspers A, Jie A, Jongen-Lavrencic M, Klein S, Klift MV, Kuball J, Lammeren-Venema DV, Legdeur MC, Loosdrecht AV, Maertens J, Kooy MVM, Moors I, Nijziel M, Obbergh FV, Oosterveld M, Pabst T, Poel MV, Sinnige H, Spertini O, Terpstra W, Tick L, Velden WV, Vekemans MC, Vellenga E, Weerdt O, Westerweel P, Stüssi G, Norden YV, Ossenkoppele G.
Impact Factor
6.126
Type
Collaborative group trials
Journal
BLOOD ADV
Year
2021
Disease Group
Leukemias
Trial
HOVON 132
Title
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Authors
Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, Ossenkoppele GJ.
Impact Factor
4.91
Type
Collaborative group trials
Journal
CANCER
Year
2021
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Authors
Leone JP, Cole BF, Regan MM, Thürlimann B, Coates AS, Rabaglio M, Giobbie-Hurder A, Gelber RD, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Goldhirsch A, Di Leo A, Colleoni M, Vaz-Luis I, Lin NU.
Impact Factor
5.742
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2021
Disease Group
Breast Cancers
Trial
IBCSG 35-07
Title
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
Authors
Jerusalem G, Farah S, Courtois A, Chirgwin J, Aebi S, Karlsson P, Neven P, Hitre E, Graas MP, Simoncini E, Abdi E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Gombos A, Ruhstaller T, Burstein HJ, Rabaglio M, Ruepp B, Ribi K, Viale G, Gelber RD, Coates AS, Loi S, Goldhirsch A, Regan MM, Colleoni M; SOLE Investigators
Impact Factor
32.976
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2021
Disease Group
Breast Cancers
Trial
IBCSG 52-15 PALLAS
Title
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
Authors
Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M.
Impact Factor
41.316
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2021
Disease Group
Lymphomas
Trial
IELSG-42
Title
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Authors
Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K
Impact Factor
10.406
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2021
Disease Group
Lung Cancers
Trial
Lung ART EORTC
Title
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial
Authors
Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, Boisselier P, Dansin E, Paumier A, Peignaux K, Thillays F, Zalcman G, Madelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, Dunant A, Edwards JG, Thomas PA, Mercier O, Bardet A.
Impact Factor
24.69
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2021
Disease Group
Gynecological Cancers
Trial
Mito/Mango 16b
Title
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Authors
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F
Impact Factor
41.316
Type
Collaborative group trials
Journal
LANCET
Year
2021
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Authors
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND
Impact Factor
79.321
Type
Swiss Cancer Institute trials
Journal
ONCOIMMUNOLOGY
Year
2020
Disease Group
Urogenital Cancers
Trial
SAKK 06/14
Title
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy
Authors
Rentsch CA, Bosshard P, Mayor G, Rieken M, Püschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoiu M, Berardi S, Hayoz S, Wicki A
Impact Factor
5.333
Type
Swiss Cancer Institute trials
Journal
INT J RADIAT ONCOL BIOL PHYS
Year
2020
Disease Group
Lung Cancers
Trial
SAKK 15/12
Title
Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurotoxicity and quality of life in patients with limited disease small-cell lung cancer. A multicenter phase II trial (SAKK 15/12)
Authors
Vees H, Caparrotti F, Eboulet EI, Xyrafas A, Fuhrer A, Meier U, Mark M, Elicin O, Aebersold DM, Zwahlen DR, Finazzi T, Allal AS, Putora PM, Martucci F, Rudolf CB, Ribi K
Impact Factor
6.203
Type
Swiss Cancer Institute trials
Journal
MED PHYS
Year
2020
Disease Group
Lung Cancers
Trial
SAKK 16/00
Title
Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients
Authors
Vuong D, Bogowicz M, Denzler S, Oliveira C, Foerster R, Amstutz F, Gabrys HS, Unkelbach J, Hillinger S, Thierstein S, Xyrafas A, Peters S, Pless M, Guckenberger M, Tanadini-Lang S.
Impact Factor
3.177
Type
Swiss Cancer Institute trials
Journal
FRONT ONCOL
Year
2020
Disease Group
Lung Cancers
Trial
SAKK 16/00
Title
Radiomics feature activation maps as a new tool for signature interpretability” for the special issue “Breakthrough in Imaging-Guided Precision Medicine in Oncology
Authors
Vuong D, Tanadini-Lang S, Wu Z, Marks R, Unkelbach J, Hillinger S, Eboulet EI, Thierstein S, Peters S, Pless M, Guckenberger M, Bogowicz M.
Impact Factor
4.848
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2020
Disease Group
Lung Cancers
Trial
SAKK 17/16
Title
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Authors
Metaxas Y, Früh M, Eboulet E I, Grosso F, Pless M, Zucali P A, Ceresoli G L, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C,. Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R
Impact Factor
14.196
Type
Swiss Cancer Institute trials
Journal
CANCER IMMUNOL IMMUN
Year
2020
Disease Group
Lung Cancers
Trial
SAKK 19/09
Title
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: An analysis of pre and post treatment biopsies in the multi-center SAKK19/09 study.
Authors
Amrein MA, Bührer ED, Amrein ML, Li Q, Rothschild S, Riether C, Jaggi R, Savic-Prince S, Bubendorf L, Gautschi O, Ochsenbein AF.
Impact Factor
4.711
Type
Swiss Cancer Institute trials
Journal
CANCER IMMUNOL IMMUN
Year
2020
Disease Group
Lung Cancers
Trial
SAKK 19/17
Title
SAKK 19/17 - Is First-Line Durvalumab in Patients with PD-L1 Positive, Advanced Non-Small Cell Lung Cancer with a Performance Status of 2 Safe?
Authors
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M
Impact Factor
5.442
Type
Swiss Cancer Institute trials
Journal
BMC CANCER
Year
2020
Disease Group
Breast Cancers
Trial
SAKK 22/99
Title
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
Authors
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle DA, Rothgiesser K, Pagani O, Thürlimann B.
Impact Factor
2.933
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2020
Disease Group
Leukemias
Trial
SAKK 32/93, SAKK 32/95, SAKK 32/98
Title
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia - A SAKK trial
Authors
Benz R, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhaeusern R, Chalandon Y, Mey U, Blum S, Rauch D, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Li Q, Feller A, Stussi G.
Impact Factor
4.91
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2020
Disease Group
Leukemias
Trial
SAKK 33/18
Title
Guideline-based indicators for adult patients with myelodysplastic syndromes
Authors
Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, Cermák J, Dinmohamed AG, Eeltink C, Eggmann S, Fenaux P, Germing U, Haschke M, Hellstrom-Lindberg E, Heger M, van de Loosdrecht AA, Passweg J, Pfeilstöcker M, Platzbecker U, Malcovati L, de Almeida AM, Mittelman M, Morgenthaler C, Steensma DP, Santini V, Stauder R, Symeonidis A, Schär S, Maddox C, de Witte T, Bohlius J, Bonadies N
Impact Factor
4.91
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2020
Disease Group
Lymphomas
Trial
SAKK 35/03
Title
Prolonged rituximab maintenance in follicular lymphoma patients: Long-term results of the SAKK 35/03 randomized trial
Authors
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E
Impact Factor
4.91
Type
Swiss Cancer Institute trials
Journal
BRIT J HAEMATOL
Year
2020
Disease Group
Lymphomas
Trial
SAKK 35/10
Title
Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial
Authors
Menter T, Hayoz S, Zucca E, Kimby E, Dirnhofer S, Tzankov A.
Impact Factor
5.401
Type
Swiss Cancer Institute trials
Journal
BRIT J HAEMATOL
Year
2020
Disease Group
Lymphomas
Trial
SAKK 35/10
Title
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy
Authors
Menter T, Tzankov A, Zucca E, Kimby E, Hultdin M, Sundström C, Beiske K, Cogliatti S, Banz Y, Cathomas G, Karjalainen-Lindsberg ML, Grobholz R, Mazzucchelli L, Sander B, Hawle H, Hayoz S, Dirnhofer S
Impact Factor
5.206
Type
Swiss Cancer Institute trials
Journal
BRIT J HAEMATOL
Year
2020
Disease Group
Lymphomas
Trial
SAKK 35/98, SAKK 35/03, SAKK 35/10
Title
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)
Authors
Moccia AA , Schär S, Hayoz S, Pirosa MC, Taverna C, Novak U, Kimby E, Ghielmini M, Zucca E
Impact Factor
5.67
Type
Swiss Cancer Institute trials
Journal
HEMATOL ONCOL
Year
2020
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial
Authors
Zucca E, Cascione L, Ruberto T, Facchinelli D, Schär S, Hayoz S, Dirnhofer S, Giovanella L, Bargetzi M, Mamot C, Ceriani L
Impact Factor
3.084
Type
Swiss Cancer Institute trials
Journal
BLOOD ADV
Year
2020
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model
Authors
Ceriani L, Gritti G, Cascione L, Pirosa MC, Polino A, Ruberto T, Stathis A, Bruno A, Moccia AA, Giovanella L, Hayoz S, Schär S, Dirnhofer S, Rambaldi A, Martinelli G, Mamot C, Zucca E
Impact Factor
4.584
Type
Swiss Cancer Institute trials
Journal
BMC CANCER
Year
2020
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Authors
Fehr M, Hawle H, Hayoz S, Thuss-Patience P, Schacher S, Riera Knorrenschild J, Dürr D, Knoefel WT, Rumpold H, Bitzer M, Zweifel M, Samaras P, Mey U, Küng M, Winterhalder R, Eisterer W, Hess V, Gérard MA, Templeton A, Stahl M, Ruhstaller T
Impact Factor
3.362
Type
Swiss Cancer Institute trials
Journal
ANN SURG
Year
2020
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
Surgical outcomes after neoadjuvant chemoradiation followed by curative surgery in patients with esophageal cancer: An intergroup phase lll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08)
Authors
von Holzen U, Schmidt S, Hayoz S, Steffen T, Grieder F, Bartsch D, Schnider A, Knoefel WT, Piessen G, Kettelhack C, Marti WR, Schäfer M, Függer R, Königsrainer A, Gloor B, Furrer M, Gérard MA, Hawle H, Walz MK, Alesina P, Ruhstaller T
Impact Factor
10.13
Type
Swiss Cancer Institute services
Journal
BONE MARROW TRANSPL
Year
2020
Disease Group
Lymphomas
Trial
-
Title
A randomized evaluation of vinorelbine versus gemcitabinechemotherapy mobilization of stem cells in myeloma patients
Authors
Jeker B, Farag S, Taleghani BM, Novak U, Mueller BU, Li Q, Betticher D, Luethi JM, Farese S, Ruefer A, Bacher U, Pabst T.
Impact Factor
3.57
Type
Swiss Cancer Institute services
Journal
JAMA NETW OPEN
Year
2020
Disease Group
Urogenital Cancers
Trial
-
Title
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Authors
Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S
Impact Factor
5.032
Type
Swiss Cancer Institute services
Journal
CANCER IMMUNOL IMMUN
Year
2020
Disease Group
Lung Cancers
Trial
-
Title
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Authors
Schmid S, Mauti LA, Friedlaender A, Blum V, Rothschild SI, Bouchaab H, Frösch P, Britschgi C, König D, Wannesson L, Janthur WD, Schär S, Demmer I, Addeo A, Jochum W, Früh M
Impact Factor
4.9
Type
Swiss Cancer Institute services
Journal
J UROLOGY
Year
2020
Disease Group
Urogenital Cancers
Trial
-
Title
Reply by Authors
Authors
Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, Bode PK, Clarke NW, Beyer J, Hermanns T
Impact Factor
5.647
Type
Other
Journal
ANN ONCOL
Year
2020
Disease Group
Lung Cancers
Trial
-
Title
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
Authors
Panje CM, Lupatsch JE, Barbier M, Pardo E, Lorez M, Dedes KJ, Aebersold DM, Plasswilm L, Gautschi O, Schwenkglenks M
Impact Factor
7.04
Type
Methodology
Journal
INT J APPROX REASON
Year
2020
Disease Group
-
Trial
-
Title
Local regression smoothers with set-valued outcome data
Authors
Li Q, Molchanov I, Molinari F, Peng S
Impact Factor
2.678
Type
Methodology
Journal
ESMO OPEN
Year
2020
Disease Group
-
Trial
-
Title
The modified PFS ratio is not ready for prime time
Authors
Kopp C, Li Q, Hayoz S
Impact Factor
5.329
Type
Meta-analysis
Journal
ARCH CARDIOVASCULAR DIS
Year
2020
Disease Group
Breast Cancers
Trial
SAKK 21/08
Title
Cardiovascular safety of BRAF and/or MEK inhibitors in cancer patients: A mixed approach combining a meta-analysis of placebo randomized-controlled trials and a WHO pharmacovigilance disproportionality analysis
Authors
Dolladille C, Font J, Bejan-Angoulvant T, Zaman K, Sassier M, Ezine E, Stefan A, Plane AF, Legallois D, Milliez P, Parienti JJ, Alexandre J.
Impact Factor
2.271
Type
Collaborative group trials
Journal
INT J GYNECOL CANCER
Year
2020
Disease Group
Gynecological Cancers
Trial
Ago-Ovar_2.29
Title
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Authors
Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F.
Impact Factor
2.095
Type
Collaborative group trials
Journal
HEMASPHERE
Year
2020
Disease Group
Leukemias
Trial
CLL 10
Title
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
Authors
Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B
Impact Factor
-
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2020
Disease Group
Leukemias
Trial
CLL 7
Title
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
Authors
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM, Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy V
Impact Factor
8.665
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2020
Disease Group
Leukemias
Trial
CML-IV
Title
High-risk additional chromosomal abnormalities at low blast counts herald death by CML
Authors
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, Kohlbrenner K, Haferlach C, Schlegelberger B, Fabarius A, Seifarth W, Spieß B, Wuchter P, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Burchert A, Brümmendorf TH, Hasford J, Hochhaus A, Saußele S, Baccarani M
Impact Factor
10.431
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2020
Disease Group
Lymphomas
Trial
EMN-02 Hovon 95
Title
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Authors
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P
Impact Factor
10.698
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2020
Disease Group
Lung Cancers
Trial
ETOP PROMISE-meso
Title
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Authors
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Nadal E, Janthur WD, López Castro R, García Campelo R, Rusakiewicz S, Letovanec I, Polydoropoulou V, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Peters S, Stahel RA.
Impact Factor
18.274
Type
Collaborative group trials
Journal
J THORAC ONCOL
Year
2020
Disease Group
Lung Cancers
Trial
ETOP SPLENDOUR
Title
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Authors
Peters S, Danson S, Hasan B, Dafni U, Reinmuth N, Majem M, Tournoy KG, Mark MT, Pless M, Cobo M, Rodriguez-Abreu D, Falchero L, Moran T, Ortega Granados AL, Monnet I, Mohorcic K, Sureda BM, Betticher D, Demedts I, Macias JA, Cuffe S, Luciani A, Sanchez JG, Curioni-Fontecedro A, Gautschi O, Price G, Coate L, von Moos R, Zielinski C, Provencio M, Menis J, Ruepp B, Pochesci A, Roschitzki-Voser H, Besse B, Rabaglio M, O'Brien MER, Stahel RA.
Impact Factor
13.357
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2020
Disease Group
Leukemias
Trial
GRAALL 2005
Title
Adult T-cell Acute Lymphoblastic Leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation
Authors
Kim R, Boissel N, Touzart A, Leguay T, Thonier F, Thomas X, Raffoux E, Huguet F, Villarese P, Fourrage C, Passini L, Hunault M, Lepretre S, Chevallier P, Braun T, Lhéritier V, Chantepie S, Maury S, Escoffre M, Tavernier E, Chalandon Y, Graux C, Macintyre E, Ifrah N, Asnafi V, Dombret H, Lhermitte L; on behalf the GRAALL group
Impact Factor
9.944
Type
Collaborative group trials
Journal
BLOOD
Year
2020
Disease Group
Leukemias
Trial
GRAALL 2005
Title
Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study
Authors
Orvain C, Balsat M, Tavernier E, Marolleau JP, Pabst T, Chevallier P, de Gunzburg N, Cacheux V, Rigal-Huguet F, Chantepie SP, Caillot D, Chalandon Y, Frayfer J, Bonmati C, Lheritier V, Ifrah NH, Dombret H, Boissel N, Hunault-Berger MM
Impact Factor
10.452
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2020
Disease Group
Lymphomas
Trial
HD 10, HD 13
Title
Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes with Conventional or High-Dose Chemotherapy
Authors
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A
Impact Factor
18.428
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2020
Disease Group
Leukemias
Trial
HD 13, HD 14, HD 15
Title
Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group
Authors
Kreissl S, Müller H, Goergen H, Meissner J, Topp M, Sökler M, Markova J, Bernhard J, Greil R, von Tresckow B, Behringer K, Rüffer JU, Flechtner HH, Möstl M, Fuchs M, Engert A, Diehl V, Borchmann P.
Impact Factor
32.956
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2020
Disease Group
Leukemias
Trial
HOVON 103 - LEN
Title
Lenalidomide added to standard intensive treatment for elderly patients with AML and high risk MDS
Authors
Ossenkoppele GJ, Breems DA, Stuessi G, van Norden Y, Bargetzi M, Biemond BJ, A von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen JJJW, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein SK, van der Klift M, van Marwijk Kooy M, Maertens J, Micheaux L, van der Poel MWM, van Rhenen A, Tick L, Valk P, Vekemans MC, van der Velden WJFM, de Weerdt O, Pabst T, Manz M, Löwenberg B
Impact Factor
10.431
Type
Collaborative group trials
Journal
BLOOD ADV
Year
2020
Disease Group
Leukemias
Trial
HOVON 135
Title
Ibrutinib added to 10-day decitabine for older patients with AML and higher-risk MDS
Authors
Huls G, Chitu DA, Pabst T, Klein SK, Stussi G, Griskevicius L, Valk PJM, Cloos J, van de Loosdrecht AA, Breems D, van Lammeren-Venema D, van Zeventer I, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz MG, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel MWM, Legdeur MC, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele GJ
Impact Factor
4.91
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2020
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Authors
Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey VJ, Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates AS, Gelber RD, Goldhirsch A, Colleoni M, Thürlimann B, Regan MM.
Impact Factor
3.94
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2020
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
Authors
Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, Hackl W, Thuerlimann B, Viale G, Di Leo A, Colleoni M, Regan MM, Loi S.
Impact Factor
18.274
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2020
Disease Group
Lymphomas
Trial
T-Cell Project
Title
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Authors
Fox CP, Civallero M, Ko YH, Manni M, Skrypets T, Pileri S, Kim SJ, Cabrera ME, Shustov AR, Chiattone CS, Horwitz SM, Dlouhy I, Spina M, Hitz F, Montoto S, Nagler A, Martinez V, De Souza CA, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Kim WS
Impact Factor
10.698
Type
Swiss Cancer Institute trials
Journal
CANCERS
Year
2019
Disease Group
Urogenital Cancers
Trial
SAKK 08/14
Title
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).
Authors
Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T
Impact Factor
5.326
Type
Swiss Cancer Institute trials
Journal
BR J CANCER
Year
2019
Disease Group
Lung Cancers
Trial
SAKK 16/08
Title
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in stage IIIB NSCLC. A multicenter phase II trial (SAKK 16/08)
Authors
Curioni-Fontecedro A, Perentes JY, Gelpke H, Xyrafas A, Bouchaab H, Mach N, Matzinger O, Stojcheva N, Frueh M, Weder W, Cathomas R, Gargiulo P, Bubendorf L, Pless M, Betticher D, Peters S
Impact Factor
5.282
Type
Swiss Cancer Institute trials
Journal
RADIOTHER ONCOL
Year
2019
Disease Group
Lung Cancers
Trial
SAKK 17/04
Title
Pattern of Failure after Adjuvant Radiotherapy Following Extrapleural Pneumonectomy of Pleural Mesothelioma in the SAKK 17/04 Trial
Authors
Riesterer O, Frank Ciernik I, Stahel RA, Xyrafas A, Aebersold DM, Plasswilm L, Mahmut Ozsahin E, Zwahlen DR, Nackaerts K, Zimmermann F, Sabrina Stark L, Weder W, Krayenbuehl J
Impact Factor
4.363
Type
Swiss Cancer Institute trials
Journal
NON-CODING RNA
Year
2019
Disease Group
Lung Cancers
Trial
SAKK 17/04
Title
miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.
Authors
Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E.
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
BMC CANCER
Year
2019
Disease Group
Breast Cancers
Trial
SAKK 22/99
Title
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Authors
Schmid S, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F, Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von Moos R, Weder P, Zaman K, Ruhstaller T.
Impact Factor
3.362
Type
Swiss Cancer Institute trials
Journal
SCI REP
Year
2019
Disease Group
Breast Cancers
Trial
SAKK 28/12
Title
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort.
Authors
Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille JC, Hawle H, Klingbiel D, Thuerlimann B, Ruhstaller T.
Impact Factor
4.525
Type
Swiss Cancer Institute trials
Journal
BLOOD
Year
2019
Disease Group
Lymphomas
Trial
SAKK 35/10
Title
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Authors
Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Berardi Vilei S, Ghielmini M, Kimby E
Impact Factor
10.452
Type
Swiss Cancer Institute trials
Journal
BLOOD CANCER J
Year
2019
Disease Group
Lymphomas
Trial
SAKK 39/10
Title
Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial (SAKK 39/10)
Authors
Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C
Impact Factor
8.125
Type
Swiss Cancer Institute trials
Journal
ANN SURG ONCOL
Year
2019
Disease Group
Gastrointestinal Cancers
Trial
SAKK 40/04
Title
ASO Author Reflections: What is the Impact of Different Rectal Reconstruction Techniques After Total Mesorectal Excision on Quality of Life?
Authors
Ribi K, Bernhard J.
Impact Factor
3.93
Type
Swiss Cancer Institute trials
Journal
ANN SURG ONCOL
Year
2019
Disease Group
Gastrointestinal Cancers
Trial
SAKK 40/04
Title
Quality of Life After Total Mesorectal Excision and Rectal Replacement: Comparing Side-to-End, Colon J-Pouch and Straight Colorectal Reconstruction in a Randomized, Phase III Trial (SAKK40/04)
Authors
Ribi K, Marti WR, Bernhard J, Grieder F, Graf M, Gloor B, Curti G, Zuber M, Demartines N, Andrieu C, Bigler M, Hayoz S, Wehrli H, Kettelhack C, Lerf B, Fasolini F, Hamel C
Impact Factor
3.93
Type
Swiss Cancer Institute trials
Journal
THER ADV MED ONCOL
Year
2019
Disease Group
Gastrointestinal Cancers
Trial
SAKK 44/00
Title
Predicting mortality and adverse events in patients with advanced pancreatic cancer (APC) treated with palliative Gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Authors
Gargiulo P, Dietrich D, Herrmann R, Bodoky G, Ruhstaller T, Scheithauer W, Glimelius B, Berardi S, Pignata S, Brauchli P
Impact Factor
0.955
Type
Swiss Cancer Institute trials
Journal
INVEST NEW DRUGS
Year
2019
Disease Group
Developmental Therapeutics
Trial
SAKK 67/15
Title
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Authors
Joerger M, Stathis A, Metaxas Y, Hess D, Mantiero M, Mark M, Volden M, Kaindl T, Engelhardt M, Larger P, Lane H, Hafner P, Levy N, Stuedeli S, Sessa C, von Moos R.
Impact Factor
2.919
Type
Swiss Cancer Institute trials
Journal
RADIAT ONCOL
Year
2019
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer. A SAKK 75/08 Substudy
Authors
Panje CM, Höng L, Hayoz S, Baracos VE, Herrmann E, Garcia Schüler H, Meier UR, Henke G, Schacher S, Hawle H, Gérard MA, Ruhstaller T, Plasswilm L
Impact Factor
2.546
Type
Swiss Cancer Institute trials
Journal
J BONE ONCOL
Year
2019
Disease Group
Supportive Care
Trial
SAKK 95/16
Title
Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Authors
Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M, Caspar CB, von Moos R
Impact Factor
2.886
Type
Swiss Cancer Institute services
Journal
J UROLOGY
Year
2019
Disease Group
Urogenital Cancers
Trial
-
Title
Characteristics and treatment outcomes of 1,375 localized and metastatic testicular Leydig cell tumors: a systematic literature review and meta-analysis
Authors
Fankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, Bode PK, Clarke NW, Beyer J, Hermanns T.
Impact Factor
5.647
Type
Swiss Cancer Institute services
Journal
CLIN GENITOURIN CANCER
Year
2019
Disease Group
Urogenital Cancers
Trial
-
Title
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.
Authors
Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R.
Impact Factor
2.45
Type
Swiss Cancer Institute services
Journal
LUNG CANCER
Year
2019
Disease Group
Lung Cancers
Trial
-
Title
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Authors
Schmid S, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M
Impact Factor
3.958
Type
Swiss Cancer Institute services
Journal
BMC UROL
Year
2019
Disease Group
Radio-Oncology
Trial
-
Title
Predictive factors for response to salvage stereotactic body radiotherapy in oligorecurrent prostate cancer limited to lymph nodes: a single institution experience
Authors
Oehler C, Zimmermann M, Adam L, Curschmann J, Sumila M, Strebel RT, Cathomas R, Li Q, Schneider U, Zwahlen DR.
Impact Factor
1.792
Type
Swiss Cancer Institute services
Journal
ANN SURG ONCOL
Year
2019
Disease Group
Breast Cancers
Trial
-
Title
Prospective Evaluation of Residual Breast Tissue after SKIn- or NIpple-Sparing Mastectomy – Results of the SKINI-Trial
Authors
Papassotiropoulos B, Güth U, Chiesa F, Rageth C, Amann E, Baege A, Elfgen C, Varga Z, Moskovszky L, Endhardt K, Masser R, Tinguely M, Farhadi J, Lardi A, Dammann F, Diebold J, Li Q, Dubsky P, Tausch C
Impact Factor
3.93
Type
Swiss Cancer Institute services
Journal
ONCOL RES TREAT
Year
2019
Disease Group
Urogenital Cancers
Trial
-
Title
Shared decision making for patients with advanced urological malignancies – Evaluation of a joint urological-oncological clinic model
Authors
Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C, Gillessen S, Engeler DS, Klingbiel D, Schmid HP, Omlin A
Impact Factor
1.09
Type
Other
Journal
FRONT ONCOL
Year
2019
Disease Group
Cancers of Head and Neck
Trial
-
Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery).
Authors
Dulguerov P, Broglie MA, Henke G, Siano M, Putora PM, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Elicin O.
Impact Factor
4.25
Type
Other
Journal
FRONT ONCOL
Year
2019
Disease Group
Cancers of Head and Neck
Trial
-
Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 2 (Radiation Oncology).
Authors
Elicin O, Putora PM, Siano M, Broglie MA, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Dulguerov P, Henke G.
Impact Factor
4.25
Type
Other
Journal
FRONT ONCOL
Year
2019
Disease Group
Cancers of Head and Neck
Trial
-
Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 3 (Medical Oncology).
Authors
Siano M, Dulguerov P, Broglie MA, Henke G, Putora PM, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Elicin O.
Impact Factor
4.25
Type
Other
Journal
FRONT ONCOL
Year
2019
Disease Group
Cancers of Head and Neck
Trial
-
Title
A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 4 (Biomarkers).
Authors
Broglie MA, Dulguerov P, Henke G, Siano M, Putora PM, Simon C, Zwahlen D, Huber GF, Ballerini G, Beffa L, Giger R, Rothschild S, Negri SV, Elicin O.
Impact Factor
4.25
Type
Methodology
Journal
J STAT PLAN INFERENCE
Year
2019
Disease Group
-
Trial
-
Title
Optimal design for multivariate multiple linear regression with set-identified response
Authors
Qiyu Li, Ilya Molchanov
Impact Factor
0.679
Type
Collaborative group trials
Journal
BR J CANCER
Year
2019
Disease Group
Breast Cancers
Trial
EORTC 10994
Title
Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes.
Authors
Bonnefoi H, MacGrogan G, Poncet C, Iggo R, Pommeret F, Grellety T, Larsimont D, Bécette V, Kerdraon O, Bibeau F, Ghnassia JP, Picquenot JM, Thomas J, Tille JC, Slaets L, Bodmer A, Bergh J, Cameron D
Impact Factor
5.791
Type
Collaborative group trials
Journal
J THORAC ONCOL
Year
2019
Disease Group
Lung Cancers
Trial
ETOP BELIEF
Title
Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.
Authors
Molina-Vila MA, Stahel RA, Dafni U, Jordana-Ariza N, Balada-Bel A, Garzón-Ibáñez M, García-Peláez B, Mayo-de-Las-Casas C, Felip E, Fontecedro AC, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Cuffe S, Bidoli P, Kammler R, Roschitzki-Voser H, Tsourti Z, Karachaliou N, Rosell R
Impact Factor
5.282
Type
Collaborative group trials
Journal
BLOOD ADV
Year
2019
Disease Group
Leukemias
Trial
GRAALL 2003, GRAALL 2005
Title
Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Authors
Alcantara M, Simonin M, Lhermitte L, Touzart A, Dourthe ME, Latiri M, Grardel N, Cayuela JM, Chalandon Y, Graux C, Dombret H, Ifrah N, Petit A, Macintyre E, Baruchel A, Boissel N, Asnafi V
Impact Factor
-
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2019
Disease Group
Lymphomas
Trial
HD 16
Title
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group
Authors
Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A.
Impact Factor
18.428
Type
Collaborative group trials
Journal
BREAST CANCER RES
Year
2019
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98
Authors
Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM
Impact Factor
3.471
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2019
Disease Group
Breast Cancers
Trial
IBCSG 22-00
Title
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Authors
Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S
Impact Factor
18.428
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2019
Disease Group
Breast Cancers
Trial
IBCSG 24-02, IBCSG 25-02
Title
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Authors
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM
Impact Factor
26.303
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2019
Disease Group
Breast Cancers
Trial
IBCSG 24-02, IBCSG 25-02
Title
Adjuvant systemic treatment of premenopausal women with hormone receptor–positive early breast cancer: Lights and shadows.
Authors
Regan MM, Fleming GF, Walley B, Francis PA, Pagani O
Impact Factor
18.428
Type
Collaborative group trials
Journal
BR J CANCER
Year
2019
Disease Group
Breast Cancers
Trial
IBCSG 35-07
Title
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Authors
Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J
Impact Factor
5.922
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2019
Disease Group
Breast Cancers
Trial
IBCSG VIII, IBCSG IX, IBCSG 18-98
Title
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.
Authors
Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G.
Impact Factor
3.94
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2019
Disease Group
Lymphomas
Trial
REMoDL-B
Title
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.
Authors
Davies AJ, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, Caddy J, Stanton L, Kazmi-Stokes S, McMillan A, Fields P, Pocock C, Collins GP, Stephens R, Cucco F, Clipson A, Sha C, Tooze R, Care MA, Griffiths G, Du MQ, Westhead DR, Burton C, Johnson PWM
Impact Factor
24.69
Type
Collaborative group trials
Journal
EUR UROL
Year
2019
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer
Authors
Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW
Impact Factor
13.938
Type
Swiss Cancer Institute trials
Journal
J THORAC ONCOL
Year
2018
Disease Group
Lung Cancers
Trial
SAKK 16/96, SAKK 16/00, SAKK 16/01
Title
Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01)
Authors
Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein A, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild S, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M
Impact Factor
10.337
Type
Swiss Cancer Institute trials
Journal
ANN SURG ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
SAKK 23/13
Title
ASO Author Reflections: Abandoning the Drains by Eliminating the Radical Procedures Necessitating the Drains.
Authors
Weber WP
Impact Factor
3.93
Type
Swiss Cancer Institute trials
Journal
ANN SURG ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
SAKK 23/13
Title
Impact of a Surgical Sealing Patch on Lymphatic Drainage after Axillary Dissection for Breast Cancer. The SAKK 23/13 Multicenter Randomized Phase III Trial
Authors
Weber WP, Tausch C, Hayoz S, Fehr MK, Ribi K, Hawle H, Lupatsch JE, Matter-Walstra K, Chiesa F, Dedes KJ, Berclaz G, Lelièvre L, Hess T, Güth U, Pioch V, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal SD, Ruhstaller T, Fehr PM, Knauer M
Impact Factor
4.041
Type
Swiss Cancer Institute trials
Journal
TRIALS
Year
2018
Disease Group
Breast Cancers
Trial
SAKK 23/16
Title
Tailored AXIllary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter randomized phase III trial.
Authors
Henke G, Knauer M, Ribi K, Hayoz S, Gérard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, Mátrai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP.
Impact Factor
1.969
Type
Swiss Cancer Institute trials
Journal
HAEMATOLOGICA
Year
2018
Disease Group
Leukemias
Trial
SAKK 33/14
Title
The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
Authors
Drexler B, Passweg JR, Tzankov A, Bigler M, Theocharides APA, Cantoni N, Keller P, Stussi G, Ruefer A, Benz R, Favre G, Lundberg P, Nienhold R, Fuhrer A, Biaggi C, Manz MG, Bargetzi M, Mendez-Ferrer S, Skoda RC
Impact Factor
5.814
Type
Swiss Cancer Institute trials
Journal
BLOOD
Year
2018
Disease Group
Lymphomas
Trial
SAKK 39/13
Title
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma
Authors
Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T
Impact Factor
15.132
Type
Swiss Cancer Institute trials
Journal
ANN SURG
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
SAKK 40/04
Title
Clinical Outcome After Rectal Replacement With Side-to-End, Colon-J-Pouch, or Straight Colorectal Anastomosis Following Total Mesorectal Excision: A Swiss Prospective, Randomized, Multicenter Trial (SAKK 40/04)
Authors
Marti WR, Curti G, Wehrli H, Grieder F, Graf M, Gloor B, Zuber M, Demartines N, Fasolini F, Lerf B, Kettelhack C, Andrieu C, Bigler M, Hayoz S, Ribi K, Hamel C
Impact Factor
8.569
Type
Swiss Cancer Institute trials
Journal
J GERIATR ONCOL
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/10
Title
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in el-derly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10.
Authors
Kienle D, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder R C, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu A, von Moos R
Impact Factor
3.359
Type
Swiss Cancer Institute trials
Journal
CANCER
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
SAKK 56/07
Title
Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumor: A Multicenter, 2-Stage Phase 2 Trial (Swiss Group for Clinical Cancer Research 56/07)
Authors
Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S
Impact Factor
6.537
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2018
Disease Group
Developmental Therapeutics
Trial
SAKK 67/13
Title
First in Human, Phase 1, Dose Escalation Pharmacokinetic and Pharmacodynamic Study of the Oral Dual PI3K and mTORC1/2 Inhibitor PQR309 in Patients with Advanced Solid Tumors (SAKK 67/13)
Authors
Wicki A, Brown N, Xyrafas A, Bize V, Hawle H, Berardi S, Cmiljanovic N, Cmiljanovic V, Stumm M, Dimitrijevic S, Herrmann R, Prêtre V, Ritschard R, Tzankov A, Hess V, Childs A, Hierro C, Rodon J, Hess D, Joerger M, von Moos R, Sessa C, Kristeleit R
Impact Factor
5.417
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/08
Title
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08)
Authors
Ruhstaller T, Thuss-Patience P, Hayoz S, Schacher S, Knorrenschild JR, Schnider A, Plasswilm L, Budach W, Eisterer W, Hawle H, Mariette C, Hess V, Mingrone W, Montemurro M, Girschikofsky M, Schmidt SC, Bitzer M, Bedenne L, Brauchli P, Stahl M
Impact Factor
11.855
Type
Swiss Cancer Institute services
Journal
BREAST CANCER
Year
2018
Disease Group
Breast Cancers
Trial
-
Title
Atypical ductal hyperplasia (ADH) and risk of underestimation: Method of tissue sampling, multicentricity and associated calcifications significantly influence upgrade rate in subsequent surgical specimens
Authors
Rageth CJ, Rubenov R, Bronz C, Dietrich D, Tausch C, Rodewald AK, Varga Z
Impact Factor
1.772
Type
Swiss Cancer Institute services
Journal
J THORAC ONCOL
Year
2018
Disease Group
Lung Cancers
Trial
-
Title
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma.
Authors
Metaxas I, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild S, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, John T.
Impact Factor
5.282
Type
Swiss Cancer Institute services
Journal
CANCER IMMUNOL IMMUN
Year
2018
Disease Group
Lung Cancers
Trial
-
Title
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Authors
Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M.
Impact Factor
4.711
Type
Swiss Cancer Institute services
Journal
J CLIN ONCOL
Year
2018
Disease Group
Urogenital Cancers
Trial
-
Title
Questioning the value of FDG PET for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group registry
Authors
Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes HS, Hentrich M, Fankhauser C, Gillessen S, Beyer J.
Impact Factor
18.428
Type
Swiss Cancer Institute services
Journal
INT J COLORECTAL DIS
Year
2018
Disease Group
Surgery
Trial
-
Title
The Growing Discrepancy between Resident Training in Colon Surgery and Rising Numbers of General Surgery Graduates
Authors
Käser SA, Rickenbacher A, Cabalzar-Wondberg D, Schneider M, Dietrich D, Misselwitz B, Clavien PA, Turina M
Impact Factor
2.383
Type
Swiss Cancer Institute services
Journal
SWISS MED WKLY
Year
2018
Disease Group
Breast Cancers
Trial
-
Title
Vitamin D levels in Swiss breast cancer survivors.
Authors
Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B.
Impact Factor
1.895
Type
Other
Journal
ANN ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
-
Title
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
Authors
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.
Impact Factor
7.04
Type
Other
Journal
RADIOTHER ONCOL
Year
2018
Disease Group
Lung Cancers
Trial
-
Title
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Authors
Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK).
Impact Factor
4.363
Type
Other
Journal
ONCOTARGET
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
-
Title
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.
Authors
Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.
Impact Factor
5.168
Type
Other
Journal
ORAL ONCOL
Year
2018
Disease Group
Cancers of Head and Neck
Trial
-
Title
Cost-effectiveness of nivolumab in the treatment of head and neck cancer
Authors
Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M
Impact Factor
4.794
Type
Other
Journal
SWISS MED WKLY
Year
2018
Disease Group
Lymphomas
Trial
-
Title
Diagnosis and treatment of follicular lymphoma: an update.
Authors
Bargetzi M, Baumann R, Cogliatti S, Dietrich PY, Duchosal M, Goede J, Hitz F, Konermann C, Lohri A, Mey U, Novak U, Papachristofilou A, Stenner F, Taverna C, Zander T, Renner C.
Impact Factor
1.895
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2018
Disease Group
Leukemias
Trial
APL 2006
Title
Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
Authors
Adès L, Thomas X, Bresler AG, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P
Impact Factor
5.814
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2018
Disease Group
Leukemias
Trial
APL 2006
Title
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Authors
Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P
Impact Factor
5.814
Type
Collaborative group trials
Journal
BREAST
Year
2018
Disease Group
Breast Cancers
Trial
BCY3/BCC 2017
Title
The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients.
Authors
Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, Paluch-Shimon S, Loibl S, Partridge AH, Demeestere I, Azim HA Jr, Peccatori FA.
Impact Factor
2.381
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2018
Disease Group
Leukemias
Trial
CML-IV
Title
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Authors
Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.
Impact Factor
10.431
Type
Collaborative group trials
Journal
HAEMATOLOGICA
Year
2018
Disease Group
Leukemias
Trial
CML-IV
Title
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Authors
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.
Impact Factor
5.814
Type
Collaborative group trials
Journal
CANCER
Year
2018
Disease Group
Lymphomas
Trial
EMN-02 Hovon 95
Title
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
Authors
Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S
Impact Factor
6.537
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2018
Disease Group
Breast Cancers
Trial
EORTC 10994
Title
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial.
Authors
Aalders KC, Touati N, Tryfonidis K, Annonay M, Litiere S, Bergh J, Bodmer A, Cameron DA, Bonnefoi HR; EORTC 10994/BIG 1-00 Study Investigators.
Impact Factor
3.94
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2018
Disease Group
Leukemias
Trial
GRAALL 2005
Title
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.
Authors
Huguet-Rigal F, Chevret S, Leguay T, Thomas X, Boissel N, Escoffre-Barbe M, Chevallier P, Hunault M, Vey N, Bonmati C, Lepretre S, Marolleau JP, Pabst T, Rousselot P, Buzyn A, Cahn JY, Lhéritier V, Béné MC, Asnafi V, Delabesse E, Macintyre E, Chalandon Y, Ifrah N, Dombret H; Group of Research on Adult ALL (GRAALL).
Impact Factor
18.428
Type
Collaborative group trials
Journal
BLOOD CANCER J
Year
2018
Disease Group
Leukemias
Trial
GRAALL 2005
Title
Monitoring of asparagine depletion and anti-l-asparaginase antibodies in adult acute lymphoblastic leukemia treated in the pediatric-inspired GRAALL-2005 trial
Authors
Paillassa J, Leguay T, Thomas X, Huguet F, Audrain M, Lheritier V, Vianey-Saban C, Acquaviva-Bourdain C, Pagan C, Dombret H, Ifrah N, Boissel N, Hunault-Berger M
Impact Factor
8.125
Type
Collaborative group trials
Journal
BLOOD
Year
2018
Disease Group
Leukemias
Trial
GRAALL 2003, GRAALL 2005
Title
PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome
Authors
Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, Thomas X, Graux C, Chalandon Y, Leguay T, Lengliné E, Konopacki J, Quentin S, Delabesse E, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Lhéritier V, Soulier J, Dombret H, Clappier E
Impact Factor
10.452
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2018
Disease Group
Lymphomas
Trial
HD 16, HD 17, HD 18
Title
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: Results from the German Hodgkin Study Group trials HD16, HD17, and HD18.
Authors
Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C.
Impact Factor
7.04
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2018
Disease Group
Lymphomas
Trial
HD 9, HD 12
Title
Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
Authors
von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.
Impact Factor
10.698
Type
Collaborative group trials
Journal
J INTERN MED
Year
2018
Disease Group
Leukemias
Trial
HOVON
Title
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.
Authors
Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK
Impact Factor
7.598
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2018
Disease Group
Leukemias
Trial
HOVON 102
Title
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Authors
Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, Oussoren-Brockhoff YJM, Snel AN, Veldhuizen D, Scholten WJ, Maertens J, Breems DA, Pabst T, Manz MG, van der Velden VHJ, Slomp J, Preijers F, Cloos J, van de Loosdrecht AA, Löwenberg B, Valk PJM, Jongen-Lavrencic M, Ossenkoppele GJ, Schuurhuis GJ
Impact Factor
10.431
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2018
Disease Group
Leukemias
Trial
HOVON 42A, HOVON 92, HOVON 102
Title
Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Authors
Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.
Impact Factor
59.558
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Authors
Ruhstaller Th, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Impact Factor
26.303
Type
Collaborative group trials
Journal
JAMA ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial
Authors
Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, Hackl W, Thuerlimann B, Viale G, Colleoni M, Regan MM, Loi S
Impact Factor
20.871
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
Authors
Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J
Impact Factor
26.303
Type
Collaborative group trials
Journal
ONCOLOGIST
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer
Authors
Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P
Impact Factor
5.306
Type
Collaborative group trials
Journal
INT J RADIAT ONCOL BIOL PHYS
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 20-98
Title
Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial
Authors
Zeidan YH, Habib JG, Ameye L, Paesmans M, de Azambuja E, Gelber RD, Campbell I, Nordenskjöld B, Gutiérez J, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Joseph DJ, Crown J, Piccart-Gebhart M, Francis PA
Impact Factor
4.495
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 22-00
Title
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Authors
Munzone E, Gray KP, Fumagalli C, Guerini-Rocco E, Láng I, Ruhstaller T, Gianni L, Kammler R, Viale G, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Barberis M, Colleoni M.
Impact Factor
3.94
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 23-01
Title
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Authors
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A
Impact Factor
24.69
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2018
Disease Group
Breast Cancers
Trial
IBCSG 27-02
Title
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial
Authors
Wapnir IL, Price KN, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Paterson AHG, Rimawi MF, Lang I, Baena-Canada JM, Thürlimann B, Mamounas EP, Geyer CE, Jr., Gelber S, Coates AS, Gelber RD, Rastogi P, Regan MM, Wolmark N, Aebi S
Impact Factor
18.428
Type
Collaborative group trials
Journal
JAMA ONCOL
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
PETACC-3 / SAKK 60/00
Title
Association of Patient Sex With Chemotherapy-Related Toxic Effects: A Retrospective Analysis of the PETACC-3 Trial Conducted by the EORTC Gastrointestinal Group.
Authors
Valérie C, Mahachie J, Mauer M, Buclin T, Van Cutsem E, Roth A, Wagner AD
Impact Factor
20.871
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2018
Disease Group
Gastrointestinal Cancers
Trial
PETACC-3 / SAKK 60/00
Title
Clinical and pharmacogenetic determinants of FOLFIRI toxicity: results of the PETACC-3 trial
Authors
Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, Fiocca R, Delorenzi M, Bosman F, Roth AD
Impact Factor
5.417
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2018
Disease Group
Lymphomas
Trial
REMoDL-B
Title
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
Authors
Sha C, Barrans S, Cucco F, Bentley MA, Care MA, Cummin T, Kennedy H, Thompson JS, Uddin R, Worrillow L, Chalkley R, van Hoppe M, Ahmed S, Maishman T, Caddy J, Schuh A, Mamot C, Burton C, Tooze R, Davies A, Du MQ, Johnson PWM, Westhead DR
Impact Factor
18.428
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2018
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Authors
Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND; STAMPEDE Investigators.
Impact Factor
7.04
Type
Collaborative group trials
Journal
EUR UROL ONCOL
Year
2018
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness
Authors
Woods BS, Sideris E, Sydes MR, Gannon MR, Parmar MBK, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR, Cook A, Corss WR, Dearnaley DP, Gale J, Gibbs J, Graham JD, Hughes R, Jones RJ, Laing R, Mason MD, Matheson D, McLaren DB, Millman R, O'Sullivan JM, Parikh O, Parker CC, Peedell C, Protheroe A, Ritchie AWS, Robinson A, Russell JM, Simms MS; Srihari N, Srinivasan R, Staffurth JN, Sundar S, Thalmann GN, Tolan S, Tran ATH, Tsang D, Wagstaff J, James ND, Sculpher MJ
Impact Factor
8.208
Type
Collaborative group trials
Journal
LANCET
Year
2018
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Authors
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR
Impact Factor
39.207
Type
Swiss Cancer Institute trials
Journal
RADIAT ONCOL
Year
2017
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy
Authors
Pirus Ghadjar, Stefanie Hayoz, Jürg Bernhard, Daniel R. Zwahlen, Jürgen Stein, Tobias Hölscher, Philipp Gut, Bülent Polat, Guido Hildebrandt, Arndt-Christian Müller, Martin P. Putora, Alexandros Papachristofilou, Corinne Schär, Alan Dal Pra, Christine Biaggi Rudolf, Peter Wust, Daniel M. Aebersold, George N. Thalmann
Impact Factor
4.328
Type
Swiss Cancer Institute trials
Journal
J TRANSL MED
Year
2017
Disease Group
Lung Cancers
Trial
SAKK 19/05
Title
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
Authors
Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M.
Impact Factor
3.694
Type
Swiss Cancer Institute trials
Journal
ENDOCR CONNECT
Year
2017
Disease Group
Breast Cancers
Trial
SAKK 21/12
Title
Phase I Clinical and Pharmacokinetic Evaluation of the Androgen Receptor Modulator CR1447 in Patients with Advanced Breast Cancer (SAKK 21/12)
Authors
M. Zweifel, B. Thürlimann, S. Riniker, P. Weder, R. von Moos, O. Pagani, M. Bigler, K. M. Rothgiesser, C. Pilop, H. Hawle, P. Brauchli, C. Tapia, W. Schoenfeld, C. Sessa
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
BMC CANCER
Year
2017
Disease Group
Breast Cancers
Trial
SAKK 26/10
Title
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Authors
BC Pestalozzi, C Tausch, KJ Dedes, C Rochlitz, S Zimmermann, R von Moos, R Winterhalder, T Ruhstaller, A Mueller, K Buser, M Borner, U Novak, C Uhlmann Nussbaum, B Seifert, M Bigler, V Bize, S Berardi Vilei, C Rageth, S Aebi
Impact Factor
3.288
Type
Swiss Cancer Institute trials
Journal
J HEMATOL ONCOL
Year
2017
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
Authors
Juskevicius D, Jucker D., Klingbiel D., Mamot C., Dirnhofer S., Tzankov A.
Impact Factor
6.263
Type
Swiss Cancer Institute trials
Journal
SUPPORT CARE CANCER
Year
2017
Disease Group
Lymphomas
Trial
SAKK 38/08
Title
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Authors
Rondeau S., Hitz F., Mey U., Enoiu M., Pabst T., Stathis A., Fischer N., Clough-Gorr K.M.
Impact Factor
2.535
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2017
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/08
Title
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
Authors
R. von Moos, D. Koeberle, S. Schacher, S. Hayoz, R.C. Winterhalder, A. Roth, G. Bodoky, P. Samaras, M.D. Berger, D. Rauch, P. Saletti, L. Plasswilm, D. Zwahlen, U.R. Meier, P. Yan, P. Izzo, D. Klingbiel, D. Bärtschi, K. Zaugg
Impact Factor
6.029
Type
Swiss Cancer Institute trials
Journal
INVEST NEW DRUGS
Year
2017
Disease Group
Developmental Therapeutics
Trial
SAKK 65/12
Title
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Authors
Stathis A, Hess D, von Moos R, Homicsko K, Griguolo G, Joerger M, Mark M, Ackermann CJ, Allegrini S, Catapano CV, Xyrafas A, Enoiu M, Berardi S, Gargiulo P, Sessa C
Impact Factor
3.484
Type
Swiss Cancer Institute trials
Journal
ANN SURG
Year
2017
Disease Group
Gastrointestinal Cancers
Trial
SAKK 75/06
Title
Recurrence Patterns and Long-Term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
Authors
Steffen T, Dietrich D, Schnider A, Kettelhack C, Huber O, Marti WR, Furrer M, Gloor B, Schiesser M, Thierstein S, Brauchli P, Ruhstaller T
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
RADIAT ONCOL
Year
2017
Disease Group
Gastrointestinal Cancers
Trial
SAKK 77/07
Title
External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26
Authors
Evelyn Herrmann, Diana Naehrig, Manfred Sassowsky, Martin Bigler, Jeroen Buijsen, Ilja Ciernik, Daniel Zwahlen, Alessandra Franzetti Pellanda, Andreas Meister, Peter Brauchli, Simona Berardi, Erika Kuettel, Jean-François Dufour, Daniel M. Aebersold
Impact Factor
2.466
Type
Swiss Cancer Institute services
Journal
GYNECOL ONCOL
Year
2017
Disease Group
Gynecological Cancers
Trial
-
Title
Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis.
Authors
Datta NR, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhüner A, Singh S, Bodis S
Impact Factor
4.198
Type
Swiss Cancer Institute services
Journal
BONE MARROW TRANSPL
Year
2017
Disease Group
Lymphomas
Trial
-
Title
NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.
Authors
Jeker B, Novak U, Mansouri Taleghani B, Baerlocher GM, Seipel K, Mueller BU, Bigler M, Betticher D, Luethi JM, Farese S, Ruefer A, Pabst T.
Impact Factor
3.57
Type
Other
Journal
INT J RADIAT ONCOL BIOL PHYS
Year
2017
Disease Group
Urogenital Cancers
Trial
-
Title
In Regard to Pisansky et al
Authors
Pirus Ghadjar, Stefanie Hayoz, Daniel R. Zwahlen, George N. Thalmann, Daniel M. Aebersold
Impact Factor
5.133
Type
Other
Journal
J CLIN ONCOL
Year
2017
Disease Group
Urogenital Cancers
Trial
-
Title
Is Dose-Intensified Salvage Radiation Therapy After Prostatectomy Beneficial?
Authors
Pirus Ghadjar, Stefanie Hayoz, Daniel R. Zwahlen, George N. Thalmann, Daniel M. Aebersold,
Impact Factor
20.982
Type
Other
Journal
EUR UROL
Year
2017
Disease Group
Urogenital Cancers
Trial
-
Title
Re: Radiation With or Without Antiandrogen Therapy in Recurrent Prostate Cancer
Authors
Marcus Beck, Stefanie Hayoz, Pirus Ghadjar
Impact Factor
16.265
Type
Other
Journal
ANN ONCOL
Year
2017
Disease Group
Lymphomas
Trial
-
Title
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas.
Authors
Karmali R, Kimby E, Ghielmini M, Flinn IW, Gordon LI, Zucca E.
Impact Factor
7.04
Type
Meta-analysis
Journal
EUR J CANCER
Year
2017
Disease Group
Lymphomas
Trial
SAKK 35/98
Title
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Authors
Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O
Impact Factor
5.417
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
EORTC 10085
Title
Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Authors
Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH.
Impact Factor
7.04
Type
Collaborative group trials
Journal
MOD PATHOL
Year
2017
Disease Group
Breast Cancers
Trial
EORTC 10085
Title
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Authors
Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Dinjens WN, van Marion R, van Diest PJ, Martens JW, van Deurzen CH
Impact Factor
6.655
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2017
Disease Group
Breast Cancers
Trial
EORTC 10085
Title
Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Authors
Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, Dijkstra NH, Schröder CP, van Asperen CJ, Linderholm B, Benstead K, Foekens R, Martens JWM, Bartlett JMS, van Deurzen CHM
Impact Factor
5.417
Type
Collaborative group trials
Journal
LANCET RESPIR MED
Year
2017
Disease Group
Lung Cancers
Trial
ETOP BELIEF
Title
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Authors
Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group
Impact Factor
15.328
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2017
Disease Group
Sarcomas
Trial
GeDDiS
Title
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Authors
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S
Impact Factor
36.418
Type
Collaborative group trials
Journal
LANCET
Year
2017
Disease Group
Lymphomas
Trial
HD 18
Title
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Authors
Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.
Impact Factor
39.207
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2017
Disease Group
Lymphomas
Trial
HD 18
Title
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Authors
Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A
Impact Factor
26.509
Type
Collaborative group trials
Journal
BLOOD
Year
2017
Disease Group
Leukemias
Trial
HOVON 102
Title
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Authors
Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ
Impact Factor
8.125
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 16-98
Title
Long-Term Follow-Up of the Intergroup Exemestane Study
Authors
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning Pe, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC
Impact Factor
26.303
Type
Collaborative group trials
Journal
ACTA ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
A high level of estrogen-stimulated proteins selects breast cancer patients treated with adjuvant endocrine therapy with good prognosis
Authors
Weischenfeldt KLH, Kirkegaard T, Rasmussen BB, Giobbie-Hurder A, Jensen MB, Ejlertsen B, Lykkesfeldt AE
Impact Factor
3.473
Type
Collaborative group trials
Journal
ACTA ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer
Authors
Lykkesfeldt AE, Iversen BR, Jensen MB, Ejlertsen B, Giobbie-Hurder A, Reiter BE, Kirkegaard T, Rasmussen BB
Impact Factor
3.473
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Authors
Giobbie-Hurder A, Ahern TP, Garber JE, Colleoni M, Láng I, Debled M, Ejlertsen B, von Moos R, Smith I, Coates AS, Goldhirsch A, Rabaglio M, Price KN, Gelber RD, Regan MM, Thürlimann B
Impact Factor
26.303
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Authors
Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW, Translational Aromatase Inhibitor Overview Group (Trans-AIOG)
Impact Factor
7.191
Type
Collaborative group trials
Journal
JCO PRECIS ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers
Authors
Willis S, Sun Y, Abramovitz M, Fei T, Young B, Lin X, Ni M, Achua J, Regan MM, Gray KP, Gray R, Wang V, Long B, Kammler R, Sparano JA, Williams C, Goldstein LJ, Salgado R, Loi S, Pruneri G, Viale G, Brown M, Leyland-Jones B
Impact Factor
-
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2017
Disease Group
Breast Cancers
Trial
IBCSG 35-07
Title
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Authors
Colleoni M, Weixiu Luo, Per Karlsson, Jacquie Chirgwin, Stefan Aebi, Guy Jerusalem, Patrick Neven, Erika Hitre, Marie-Pascale Graas, Edda Simoncini, Claus Kamby, Alastair Thompson, Sibylle Loibl, Joaquín Gavilá, Katsumasa Kuroi, Christian Marth, Bettina Müller, Seamus O'Reilly, Vincenzo Di Lauro, Andrea Gombos, Thomas Ruhstaller, Harold Burstein, Karin Ribi, Jürg Bernhard, Giuseppe Viale, Rudolf Maibach, Manuela Rabaglio-Poretti, Richard D Gelber, Alan S Coates, Angelo Di Leo, Meredith M Regan, Aron Goldhirsch
Impact Factor
24.69
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2017
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.
Authors
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR
Impact Factor
79.285
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2017
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
Authors
Mason MD, Clarke NW, James ND, Dearnaley DP, Spears MR, Ritchie AW, Attard G, Cross W, Jones RJ, Parker CC, Russell JM, Thalmann GN, Schiavone F, Cassoly E, Matheson D, Millman R, Rentsch CA, Barber J, Gilson C, Ibrahim A, Logue J, Lydon A, Nikapota AD, O'Sullivan JM, Porfiri E, Protheroe A, Srihari NN, Tsang D, Wagstaff J, Wallace J, Walmsley C, Parmar MK, Sydes MR; STAMPEDE Investigators..
Impact Factor
26.303
Type
Swiss Cancer Institute trials
Journal
PROSTATE
Year
2016
Disease Group
Urogenital Cancers
Trial
SAKK 08/11
Title
Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: A multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08/11)
Authors
Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D, Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen S
Impact Factor
3.778
Type
Swiss Cancer Institute trials
Journal
BJU INT
Year
2016
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.
Authors
Ghadjar P, Hayoz S, Genitsch V, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Putora MP, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Khanfir K, Budach V, Aebersold DM, Thalmann GN
Impact Factor
4.439
Type
Swiss Cancer Institute trials
Journal
STRAHLENTHER ONKOL
Year
2016
Disease Group
Cancers of Head and Neck
Trial
SAKK 10/94
Title
Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers : Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94)
Authors
Ghadjar P, Pöttgen C, Joos D, Hayoz S, Baumann M, Bodis S, Budach W, Studer G, Stromberger C, Zimmermann F, Kaul D, Plasswilm L, Olze H, Bernier J, Wust P, Aebersold DM, Budach V.
Impact Factor
2.914
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2016
Disease Group
Lung Cancers
Trial
SAKK 16/01
Title
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
Authors
Früh M, Ris H.B. , Xyrafas A. , Peters S. , Mirimanoff RO. , Gautschi O. , Pless M. , Stupp R.
Impact Factor
7.04
Type
Swiss Cancer Institute trials
Journal
CLIN LUNG CANCER
Year
2016
Disease Group
Lung Cancers
Trial
SAKK 19/09
Title
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous NoneSmall-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Authors
Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF
Impact Factor
3.104
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2016
Disease Group
Breast Cancers
Trial
SAKK 22/99
Title
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Authors
Pagani O, Klingbiel D, Ruh-staller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos RV, Zaman K, Goldhirsch A; Swiss Group for Clinical
Impact Factor
7.04
Type
Swiss Cancer Institute trials
Journal
BMC CANCER
Year
2016
Disease Group
Breast Cancers
Trial
SAKK 24/09
Title
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. Bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Authors
Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Kyung-Jae N, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R
Impact Factor
3.288
Type
Swiss Cancer Institute trials
Journal
HEMATOL ONCOL
Year
2016
Disease Group
Lymphomas
Trial
SAKK 37/05
Title
Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).
Authors
Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M.
Impact Factor
3.084
Type
Swiss Cancer Institute trials
Journal
BRIT J HAEMATOL
Year
2016
Disease Group
Lymphomas
Trial
SAKK 38/08
Title
Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy – SAKK 38/08
Authors
Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U.
Impact Factor
4.71
Type
Swiss Cancer Institute trials
Journal
INT J COLORECTAL DIS
Year
2016
Disease Group
Gastrointestinal Cancers
Trial
SAKK 40/00
Title
Prospective multicenter registration study of colorectal cancer: significant variations in radicality and oncosurgical quality-Swiss Group for Clinical Cancer Research Protocol SAKK 40/00.
Authors
Maurer CA, Dietrich D, Schilling MK, Metzger U, Laffer U, Buchmann P, Lerf B, Villiger P, Melcher G, Klaiber C, Bilat C, Brauchli P, Terracciano L, Kessler K.
Impact Factor
2.383
Type
Swiss Cancer Institute trials
Journal
CLIN COLORECTAL CANC
Year
2016
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/06
Title
Bevacizumab Continuation Versus Treatment Holidays After First-Line Chemotherapy With Bevacizumab in Patients With Metastatic Colorectal Cancer: A Health Economic Analysis of a Randomized Phase 3 Trial (SAKK 41/06).
Authors
Matter-Walstra K, Schwenkglenks M, Betticher D, von Moos R, Dietrich D, Baertschi D, Koeberle D.
Impact Factor
2.81
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2016
Disease Group
Gastrointestinal Cancers
Trial
SAKK 77/08
Title
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)
Authors
J.-F. Dufour, G. Demeter, Q. Li, K. Ribi, P. Samaras, P. Saletti, A. D. Roth, D. Horber, M. Buehlmann, A. D. Wagner, M. Montemurro, G. Lakatos, J. Feilchenfeldt, M. Peck-Radosavljevic, D. Rauch, B. Tschanz, G. Bodoky
Impact Factor
9.269
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2016
Disease Group
Supportive Care
Trial
SAKK 95/06
Title
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Authors
Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle D
Impact Factor
7.04
Type
Swiss Cancer Institute services
Journal
J BIOMED MATER RES A
Year
2016
Disease Group
-
Trial
-
Title
A systematic review and meta-analysis on the influence of biological implant surface coatings on periimplant bone formation.
Authors
Jenny G, Jauernik J, Bierbaum S, Bigler M, Grätz KW, Rücker M, Stadlinger B.
Impact Factor
3.076
Type
Swiss Cancer Institute services
Journal
J THORAC ONCOL
Year
2016
Disease Group
Lung Cancers
Trial
-
Title
Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with de novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKI).
Authors
Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M
Impact Factor
5.282
Type
Swiss Cancer Institute services
Journal
INT J HYPERTHER
Year
2016
Disease Group
Urogenital Cancers
Trial
-
Title
Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: A systematic review with conventional and network meta-analyses.
Authors
Rogers S, Klingbiel D, Gómez S, Puric E, Bodis S.
Impact Factor
2.65
Type
Swiss Cancer Institute services
Journal
J CLIN ONCOL
Year
2016
Disease Group
Urogenital Cancers
Trial
-
Title
Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma
Authors
Fischer S., Tandstad T., Wheater M., Porfiri E., Fléchon A., Aparicio J., Klingbiel D., Skrbinc B., Basso U., Shamash J., Lorch A., Dieckmann KP, Cohn-Cedermark G., Ståhl O, Chau C., Arriola E., Marti K., Hutton P., Laguerre B., Maroto P., Beyer J., Gillessen S.
Impact Factor
18.428
Type
Other
Journal
J THORAC ONCOL
Year
2016
Disease Group
Lung Cancers
Trial
-
Title
A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing.
Authors
Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; SAKK
Impact Factor
5.28
Type
Other
Journal
JAMA ONCOL
Year
2016
Disease Group
Gastrointestinal Cancers
Trial
-
Title
Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer Requirements for Accurate Prognosis Assessment.
Authors
Klingbiel D, Tejpar S
Impact Factor
16.559
Type
Other
Journal
BREAST CANCER RES TR
Year
2016
Disease Group
Breast Cancers
Trial
-
Title
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Authors
Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.
Impact Factor
3.94
Type
Other
Journal
J CLIN ONCOL
Year
2016
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Reply to C. Cozzarini et al
Authors
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Aebersold DM.
Impact Factor
18.428
Type
Meta-analysis
Journal
J CLIN ONCOL
Year
2016
Disease Group
Lymphomas
Trial
SAKK 35/98
Title
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Authors
Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ
Impact Factor
18.428
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2016
Disease Group
Leukemias
Trial
CLL 10
Title
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority Trial.
Authors
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M
Impact Factor
24.69
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2016
Disease Group
Melanomas
Trial
EORTC 18952
Title
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Authors
Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, Salès F, Keilholz U, de Schaetzen G, Testori A; EORTC Melanoma Group.
Impact Factor
5.417
Type
Collaborative group trials
Journal
J THORAC ONCOL
Year
2016
Disease Group
Lung Cancers
Trial
ETOP EMPHASIS
Title
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial
Authors
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF
Impact Factor
5.282
Type
Collaborative group trials
Journal
BLOOD
Year
2016
Disease Group
Leukemias
Trial
HOVON 42, HOVON 43, HOVON 81, HOVON 92
Title
Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia
Authors
Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, Löwenberg B, Leebeek FWG.
Impact Factor
13.164
Type
Collaborative group trials
Journal
JAMA ONCOL
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence
Authors
Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, DellÔrto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C
Impact Factor
-
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Authors
Chrigwin J, Gibbie-Hurder A, Coates AS, Price KN, Ejlertsen B, Debled M, Gelber RD, Goldhirsch A, Smith I, Rabaglio M, Forbes JF, Neven P, Láng I, Colleoni M, Thürlimann B
Impact Factor
24.008
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG 22-00
Title
Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
Authors
Colleoni M, Gray KP, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi EA, Gomez HL, Linderholm BK, Puglisi F, Tondini C, Kralidis E, Eniu A, Cagossi K, Rauch D, Chirgwin J, Gelber RD, Regan MM, Coates AS, Price KN, Viale G, Goldhirsch A.
Impact Factor
24.008
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG 22-00
Title
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Authors
Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancello G, Munzone E, Gelber RD, Regan MM, Colleoni M.
Impact Factor
3.94
Type
Collaborative group trials
Journal
BR J CANCER
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG 24-02
Title
Adjuvant ovarian function suppression and cognitive function in women with breast cancer
Authors
Regan MM, Ribi K Francis PA Puglisi F Bellet M, Spazzapan S, Karlsson P, Budman DR, Zaman K, Abdi EA, Domchek SM, Feng Y, Price KN, Coates AS, Gelber RD, Maruff P, Boyle F, Forbes JF, Ahles T, Fleming GF, Bernhard J
Impact Factor
6.176
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG 25-02
Title
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT Trial.
Authors
Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA.
Impact Factor
3.94
Type
Collaborative group trials
Journal
INT J RADIAT ONCOL BIOL PHYS
Year
2016
Disease Group
Breast Cancers
Trial
IBCSG VI, IBCSG VII
Title
Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII
Authors
Karlsson P, Cole BF, Price KN, Gelber RD, Coates AS, Goldhirsch A, Castiglione M, Colleoni M, Gruber G
Impact Factor
5.133
Type
Collaborative group trials
Journal
LANCET
Year
2016
Disease Group
Breast Cancers
Trial
IBIS-II
Title
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Authors
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators.
Impact Factor
39.207
Type
Collaborative group trials
Journal
LANCET HAEMATOL
Year
2016
Disease Group
Lymphomas
Trial
IELSG-32
Title
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the fi rst randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Authors
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G
Impact Factor
7.123
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2016
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
Authors
Nicholas D James, Matthew R Sydes, Malcolm D Mason, Noel W Clarke, John Anderson, David P Dearnaley, John Dwyer, Gordana Jovic, Alastair W S Ritchie, J Martin Russell, Karen Sanders, George N Thalmann, Gian?lippo Bertelli, Alison J Birtle, Joe M O’Sullivan, Andrew Protheroe, Denise Sheehan, Narayanan Srihari, Mahesh K B Parmar, for the STAMPEDE investigators
Impact Factor
33.9
Type
Collaborative group trials
Journal
HEMATOL ONCOL
Year
2016
Disease Group
Lymphomas
Trial
T-Cell Project
Title
Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study
Authors
Bellei M, Sabattini E, Pesce EA, Ko YH, Kim WS, Cabrera ME, Martinez V, Dlouhy I, Paes RP, Barrese T, Vassallo J, Tarantino V, Vose J, Weisenburger D, Rüdiger T, Federico M, Pileri S
Impact Factor
3.118
Type
Swiss Cancer Institute trials
Journal
PROSTATE CANCER P D
Year
2015
Disease Group
Urogenital Cancers
Trial
SAKK 08/09
Title
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)
Authors
M Joerger, Van Schaik, R.H.N., Becker, M.L., Hayoz, S., Pollak, M., Cathomas, R., Winterhalder, R., Gillessen, S., Rothermundt, C.
Impact Factor
3.425
Type
Swiss Cancer Institute trials
Journal
J CLIN ONCOL
Year
2015
Disease Group
Urogenital Cancers
Trial
SAKK 09/10
Title
Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
Authors
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Kaouthar K, Wust P, Thalmann GN, Aebersold DM.
Impact Factor
18.428
Type
Swiss Cancer Institute trials
Journal
RADIAT ONCOL
Year
2015
Disease Group
Cancers of Head and Neck
Trial
SAKK 10/94
Title
Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94)
Authors
Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, Bernier J, Studer G, Plasswilm L, Budach V, Aebersold DM
Impact Factor
2.546
Type
Swiss Cancer Institute trials
Journal
LANCET
Year
2015
Disease Group
Lung Cancers
Trial
SAKK 16/00
Title
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Authors
Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S
Impact Factor
44.002
Type
Swiss Cancer Institute trials
Journal
LANCET ONCOL
Year
2015
Disease Group
Lung Cancers
Trial
SAKK 17/04
Title
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 Trial.
Authors
Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W
Impact Factor
24.69
Type
Swiss Cancer Institute trials
Journal
LUNG CANCER
Year
2015
Disease Group
Lung Cancers
Trial
SAKK 17/04
Title
Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases.
Authors
Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E.
Impact Factor
3.958
Type
Swiss Cancer Institute trials
Journal
CLIN CANCER RES
Year
2015
Disease Group
Lung Cancers
Trial
SAKK 19/05
Title
Gene expression signatures predictive of bevacizumab/erlotinib therapeutic benefit in advanced non-squamous non-small cell lung cancer patients (SAKK 19/05 trial).
Authors
Franzini A, Baty F, Macovei II, Dürr O, Droege C, Betticher D, Grigoriu BD, Klingbiel D, Zappa F, Brutsche MH
Impact Factor
8.722
Type
Swiss Cancer Institute trials
Journal
CLIN LUNG CANCER
Year
2015
Disease Group
Lung Cancers
Trial
SAKK 19/09
Title
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced NoneSmall-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Authors
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF
Impact Factor
3.104
Type
Swiss Cancer Institute trials
Journal
EUR J CANCER
Year
2015
Disease Group
Breast Cancers
Trial
SAKK 21/08
Title
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.
Authors
Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P.
Impact Factor
5.417
Type
Swiss Cancer Institute trials
Journal
PLOS ONE
Year
2015
Disease Group
Breast Cancers
Trial
SAKK 28/12
Title
Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
Authors
Zsuzsanna Varga, Estelle Cassoly, Qiyu Li, Christian Oehlschlegel, Coya Tapia, Hans Anton Lehr, Dirk Klingbiel, Beat Thürlimann, Thomas Ruhstaller
Impact Factor
3.23
Type
Swiss Cancer Institute trials
Journal
J CLIN ONCOL
Year
2015
Disease Group
Lymphomas
Trial
SAKK 35/03
Title
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Authors
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M
Impact Factor
18.428
Type
Swiss Cancer Institute trials
Journal
J CLIN ONCOL
Year
2015
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Authors
Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.
Impact Factor
18.428
Type
Swiss Cancer Institute trials
Journal
J HEMATOL ONCOL
Year
2015
Disease Group
Lymphomas
Trial
SAKK 38/07
Title
Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
Authors
Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.
Impact Factor
4.812
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2015
Disease Group
Gastrointestinal Cancers
Trial
SAKK 41/06
Title
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
Authors
Koeberle D, Betticher DC, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Frueh M, Kueng M, Popescu RA, Schacher S, Hess V, Herrmann R.
Impact Factor
9.269
Type
Swiss Cancer Institute trials
Journal
ANN ONCOL
Year
2015
Disease Group
Gastrointestinal Cancers
Trial
SAKK 43/99
Title
Pre-operative versus post-operative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
Authors
Fazio N, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R, Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, Zampino MG, Huber O11, Goldhirsch A, de Braud F, Roth AD
Impact Factor
7.04
Type
Swiss Cancer Institute trials
Journal
HAEMATOLOGICA
Year
2015
Disease Group
Developmental Therapeutics
Trial
SAKK 65/08
Title
Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Authors
Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C, Xyrafas A, Hawle H, Berthod G, Overkleeft HS, Sessa C, Huitema A, Pabst T, von Moos R, Hess D, Mey UJ
Impact Factor
5.814
Type
Swiss Cancer Institute services
Journal
J BIOMED INFORM
Year
2015
Disease Group
-
Trial
-
Title
High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA)
Authors
Klingbiel D, Baty F, Klingbiel D, Zappa F, Brutsche M .
Impact Factor
2.482
Type
Swiss Cancer Institute services
Journal
INT J RADIAT ONCOL BIOL PHYS
Year
2015
Disease Group
Breast Cancers
Trial
-
Title
Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis
Authors
Puric E, Klingbiel D, Gomez S, Bodis S.
Impact Factor
4.258
Type
Swiss Cancer Institute services
Journal
RADIAT ONCOL
Year
2015
Disease Group
Urogenital Cancers
Trial
-
Title
Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.
Authors
Zips D, Heinrich V, Lamprecht U, Voigt O, Burock S, Budach V, Wust P, Ghadjar P.
Impact Factor
2.546
Type
Swiss Cancer Institute services
Journal
ANN ONCOL
Year
2015
Disease Group
Urogenital Cancers
Trial
-
Title
Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ cell tumour: Results from a 17 year UK experience.
Authors
Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T.
Impact Factor
7.04
Type
Swiss Cancer Institute services
Journal
SUPPORT CARE CANCER
Year
2015
Disease Group
Lung Cancers
Trial
-
Title
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.
Authors
Volk V, Cathomas R, Mark M, von Moos R, Klingbiel D, Brossart P, Mey U.
Impact Factor
2.364
Type
Other
Journal
RADIAT ONCOL
Year
2015
Disease Group
Gastrointestinal Cancers
Trial
-
Title
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland.
Authors
Putora PM, Bedenne L, Budach W, Eisterer W, Van Der Gaast A, Jäger R, Van Lanschot JJ, Mariette C, Schnider A, Stahl M, Ruhstaller T.
Impact Factor
2.546
Type
Meta-analysis
Journal
ANN ONCOL
Year
2015
Disease Group
Lymphomas
Trial
SAKK 35/98
Title
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-Analysis
Authors
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C1, Zucca E, Herold M, Ghielmini M, Thieblemont C.
Impact Factor
7.04
Type
Collaborative group trials
Journal
CANCER
Year
2015
Disease Group
Leukemias
Trial
APL 2006
Title
Evolving Characteristics and Outcome of Secondary Acute Promyelocytic Leukemia (APL): A Prospective Analysis by the French-Belgian-Swiss APL Group
Authors
Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, Fenaux P; French-Belgian-Swiss APL Group
Impact Factor
5.649
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2015
Disease Group
Leukemias
Trial
APL PROMYSE Reg
Title
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.
Authors
Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, Ramadan SM, Pagoni M, Breccia M, Huerta AJ, Nloga AM, González-Sanmiguel JD, Schmidt A, Lambert JF, Lehmann S, Di Bona E, Cassinat B, Hofmann WK, Görlich D, Sauerland MC, Fenaux P, Sanz M
Impact Factor
12.104
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2015
Disease Group
Gastrointestinal Cancers
Trial
CAPP2
Title
Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Authors
Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC.
Impact Factor
20.982
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2015
Disease Group
Leukemias
Trial
CML IIIA
Title
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
Authors
Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baumann H, Kuse R, Schmitz N, Wehmeier A, Fischer JTH, Ho AD, Wilhelm M, Goebeler M-E, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kold H-J, Büusche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R for the SAKK and the German CML Study Group
Impact Factor
12.104
Type
Collaborative group trials
Journal
LANCET
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
Authors
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Impact Factor
44.002
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Authors
Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM
Impact Factor
4.085
Type
Collaborative group trials
Journal
BREAST CANCER RES TR
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer
Authors
Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM, in behalf of the BIG 1-98 Collaborative Group
Impact Factor
4.805
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
Authors
Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group
Impact Factor
9.269
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
Authors
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Debled M, Price KN, Regan MM, Coates AS, Goldhirsch A
Impact Factor
20.982
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 20-98
Title
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
Authors
Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J
Impact Factor
6.163
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 34-05
Title
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Authors
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS
Impact Factor
55.873
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2015
Disease Group
Breast Cancers
Trial
IBCSG 36-07
Title
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
Authors
Piccart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA
Impact Factor
18.443
Type
Collaborative group trials
Journal
LANCET
Year
2015
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Authors
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB, O'Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK; STAMPEDE investigators.
Impact Factor
44.002
Type
Collaborative group trials
Journal
JAMA ONCOL
Year
2015
Disease Group
Urogenital Cancers
Trial
STAMPEDE
Title
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer Data From Patients in the Control Arm of the STAMPEDE Trial
Authors
James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD; Parker CC, Ritchie AWS, Russell JM, Schiavone F, Attard G, de Bono JS, Birtle A, Engeler DS, Elliott T, Matheson D, O'Sullivan J, Pudney D, Srihari N, Wallace J, Barber J, Syndikus I, Parmar MKB, Sydes MR for the STAMPEDE Investigators
Impact Factor
-
Type
Swiss Cancer Institute trials
Journal
NAT COMMUN
Year
2025
Disease Group
Lung Cancers
Trial
SAKK 16/14
Title
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Authors
Schmid D, Sobottka B, Manzo M, Trüb M, Leonards K, Herzig P, Oyewole OR, Jermann P, Hayoz S, Savic Prince S, Tochtermann G, Natoli M, Pless M, Bettini A, Früh M, Mauti LA, Britschgi C, Peters S, Mark M, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Gonzalez M, Alborelli I, Rothschild SI, Koelzer VH, Zippelius A
Impact Factor
15.7
Type
Swiss Cancer Institute trials
Journal
ONCOLOGY
Year
2025
Disease Group
Developmental Therapeutics
Trial
SAKK 80/19_AlpineTIR
Title
Unsupervised dynamic ePRO reporting of immunotherapy related symptoms in cancer patients
Authors
Stauffacher AK, von Stockar L, Witschel HF, Hayoz S, Petrausch U, Schmid T, Jakob A, Kullak-Ublick GA, Trojan A
Impact Factor
1.8
Type
Swiss Cancer Institute services
Journal
CANCERS
Year
2025
Disease Group
Leukemias
Trial
-
Title
Prognostic impact of the AML60+ score for elderly patients with acute myeloid leukemia treated with hypomethylating agents – a retrospective multicentric analysis
Authors
Petermilch V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede J, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T
Impact Factor
5.326
Type
Other
Journal
healthbook TIMES Oncology Hematology
Year
2025
Disease Group
Lung Cancers
Trial
-
Title
Lung Cancer Research from the Swiss Cancer Institute: ELCC 2025 Highlights
Authors
Rothschild SI, Waibel C, König D, Hayoz S, Mauti LA
Impact Factor
-
Type
Meta-analysis
Journal
ESMO OPEN
Year
2025
Disease Group
Developmental Therapeutics
Trial
phase-1_retrospective data analysis
Title
A retrospective analysis of Phase I and Phase I/II clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK)
Authors
Koster KL, Colombo I, Hayoz S, Eckhardt K, Rojas Mora A, Hess D, Britschgi C, Haefliger S, Imbimbo M, Bertoni F, Homicsko K, von Moos R, Sessa C, Joerger M, Stathis A
Impact Factor
8.3
Type
Collaborative group trials
Journal
LANCET ONCOL
Year
2025
Disease Group
Lymphomas
Trial
HD 21
Title
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial
Authors
Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Hellmuth JC, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Jablonski J, Damaschin C, Robertz AS, Rosenbrock J, Fuchs M, Borchmann P, Behringer K
Impact Factor
35.9
Type
Collaborative group trials
Journal
LEUKEMIA
Year
2025
Disease Group
Leukemias
Trial
HOVON 132
Title
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial
Authors
Mocking TR, Haaksma LH, Reuvekamp T, Kelder A, Scholten WJ, Ngai LL, Breems DA, Fischer T, Gjertsen BT, Griškevicius L, Juliusson G, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, van de Loosdrecht AA, Cloos J, Bachas C
Impact Factor
12.8
Type
Collaborative group trials
Journal
JCO PRECIS ONCOL
Year
2025
Disease Group
Breast Cancers
Trial
IBCSG 18-98
Title
Genomic characterization and prognostic significance of HER2-low, hormone receptor-positive, early breast cancers from the BIG 1-98 and SOFT clinical trials
Authors
Luen SJ, Brown LC, van Geelen CT, Savas P, Kammler R, Dell’Orto P, Biasi O, Coates AS, Gelber RD, Thuerlimann B, Colleoni M, Fleming GF, Francis PA, Regan MM, Viale G, Loi S
Impact Factor
5.6
Type
Collaborative group trials
Journal
CANCER
Year
2025
Disease Group
Breast Cancers
Trial
IBCSG 25-02
Title
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT
Authors
Ribi K, Cole BF, Fleming GF, Walley BA, Francis PA, Abdi E, Burstein HJ, Cheng KL, Chia SKL, Dakhil SR, Davidson NE, Della-Fiorentina SA, Frith AE, Levine E, Lupichuk S, Pritchard K, Salim M, Stearns V, Stewart J, Valero V, van der Westhuizen A, Pagani O, Loi S, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J
Impact Factor
5.1
Type
Collaborative group trials
Journal
EUR J CANCER
Year
2025
Disease Group
Breast Cancers
Trial
IBCSG 35-07
Title
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial
Authors
Biganzoli G, Richard F, Isnaldi E, Marano G, Boracchi P, Maetens M, Floris G, Neven P, Jerusalem G, Munzone E, Hitre E, Gombos A, Thompson A, Aebi S, Kammler R, Dell’Orto P, Viale G, Regan MM, Colleoni M, Biganzoli E, Desmedt C
Impact Factor
7.1
Type
Collaborative group trials
Journal
BREAST
Year
2025
Disease Group
Breast Cancers
Trial
IBCSG 48-14 POSITIVE
Title
Breastfeeding after hormone receptor-positive breast cancer: Results from the Positive Trial
Authors
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr
Impact Factor
7.9
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2025
Disease Group
Breast Cancers
Trial
IBCSG 48-14 POSITIVE
Title
Breastfeeding after hormone receptor-positive breast cancer: Results from the Positive Trial
Authors
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr
Impact Factor
42.1
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2025
Disease Group
Breast Cancers
Trial
IBCSG 55-17 TOUCH
Title
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
Authors
Malorni L, Tyekucheva S, Gombos A, Hasler-Stub U, Zamgani C, Chakiba-Brugere, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Rueep B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L
Impact Factor
65.4
Type
Collaborative group trials
Journal
BLOOD
Year
2024
Disease Group
Leukemias
Trial
GRAALL 2014
Title
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia
Authors
Chalandon Y, Rousselot P, Chevret S, Cayuela JM, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie S, Thomas X, Vincent L, Berthon C, Hicheri Y, Raffoux E, Escoffre-Barbe M, Plantier I, Joris M, Turlure P, Pasquier F, Belhabri A, Guepin GR, Blum S, Gregor M, Lafage-Pochitaloff M, Quessada J, Lhéritier V, Clappier E, Boissel N, Dombret H
Impact Factor
23.1
Type
Collaborative group trials
Journal
J CLIN ONCOL
Year
2024
Disease Group
Leukemias
Trial
GRAALL 2014
Title
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study
Authors
Kim R, Chalandon Y, Rousselot P, Cayuela JM, Huguet F, Balsat M, Passet M, Chevallier P, Hicheri Y, Raffoux E, Leguay T, Chantepie S, Maury S, Hayette S, Solly F, Braun T, De Prijck B, Cacheux V, Salanoubat C, Farnault L, Guibaud I, Lamarque M, Gastaud L, Lemasle E, Brissot E, Tavernier E, Bilger K, Villate A, Soulier J, Graux C, Lhéritier V, Dombret H, Boissel N, Clappier E
Impact Factor
42.1
Type
Collaborative group trials
Journal
J IMMUNOTHER CANCER
Year
2023
Disease Group
Lung Cancers
Trial
ETOP PROMISE-meso
Title
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Authors
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA
Impact Factor
10.9
Type
Collaborative group trials
Journal
LANCET
Year
2022
Disease Group
Sarcomas
Trial
EURO EWING 2012
Title
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial
Authors
Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K.
Impact Factor
18.97
Type
Collaborative group trials
Journal
ANN ONCOL
Year
2022
Disease Group
Breast Cancers
Trial
IBCSG 50-14 OLYMPIA
Title
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Authors
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus
Impact Factor
50.5
Type
Collaborative group trials
Journal
NEW ENGL J MED
Year
2021
Disease Group
Breast Cancers
Trial
IBCSG 50-14 OLYMPIA
Title
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Authors
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr
Impact Factor
176.079

No results found for your filtering